Bio2008 06-16-08

AN ADVERTISING SUPPLEMENT TO THE
BIO
2008
IN COLLABORATION WITH
FOCUS
ON RESEARCH
AND DEVELOPMENT
WHILE WE HANDLE
YOUR REAL ESTATE NEEDS!
Minnesota Innovation Center Nexus University City 3500 Paramount Parkway Procter & Gamble 801 / 887 Great Northern Way
Science Center Woods Corners Facility
Research & Technology Park Life Science / R&D campus Laboratory Facility Norwich Technical Center Laboratory / Office
Phase I – 251,000-sf build-to-suit 161,871-sf for lease / build-to-suit 61,380-sf for lease 335,000-sf / 88 acres for sale 164,000-sf for lease or for sale
Minneapolis, MN San Diego, CA Morrisville, NC Norwich, NY Adjacent 2.62-acre development
site for sale
Vancouver, BC
The Colliers Life Sciences Group allows you the world exclusively specializing in life sciences
to focus on serving your clients, investors, and real estate, we provide expertise and exceptional
employees while we solve your unique, complex service:
real estate challenges.
Leasing • Investment Sales • Development •
With over 100 experienced professionals around Property Management • Finance
To learn more about our global Life Sciences Real Estate Group, please contact:
Tom Mercer Milton Charbonneau, SIOR, CCIM Sarah Wager
Senior Vice President Vice President Practice Group Coordinator
858.677.5388 732.271.6306 617.722.0221
tom.mercer@colliers.com milt.charbonneau@colliers.com sarah.wager@colliers.com
www.colliers.com/lifesciences Our Knowledge is your Property

BIO 2008
Letter From the Publishers
We take this opportunity to introduce our inaugural biotech supplement highlighting the region’s biotech industry, the 2008 Biotechnology
Industry Organization International Convention and Canada’s key role in our local industry.
The BIO convention is the premier gathering of everyone involved in the life sciences industry, and this
advertising supplement covers many of the key topics and discussion areas that conventioneers will face
this week.
This conference is an important event for the biotech sector. Each day scientists in the biotech industry
are inventing a future of better health care for Americans and other people throughout the world.
With the region’s biotech cluster employing more than 38,000 workers, it’s no surprise that San Diego
Armon Mills Reo Carr
County is a leader in the United States, not to mention the rest of the world. The biotech community reaches
into nearly every corner of the San Diego economy.
Indeed, we are a powerhouse to be reckoned with when it comes to our strong base in the life sciences, but we are willing to partner with
other regions of the world in the ongoing quest to better humankind through the development of new pharmaceuticals and medical products.
So, we welcome the 2008 BIO International Convention and urge the more than 20,000 expected attendees to enjoy beautiful San Diego.
There is lots to see and do while you visit this veritable wonderland of sea and sun. And we trust your attendance at BIO’s annual conference
proves a valuable professional experience.
Thank you,
Armon Mills Reo Carr

President & Publisher Associate Publisher
San Diego Business Journal San Diego Business Journal
+VOF "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM #*04VQQMFNFOU

BIO 2008
BIO International Convention Draws
Top Innovators and Top Dollars
By Marion Webb gions in the world, Southern Califor- ple (from outside San Diego) get to and a stage for presentations.
The 2008 Biotechnology Industry nia is an ideal setting for our event,” know the biotech cluster and people Among the sponsors of the
Organization’s conference to be held Greenwood said. “It will also show- from San Diego will take advantage $400,000 pavilion are the city of San
at the San Diego Convention Center case San Diego to an international of building relationships.” Diego, the Labor and Workforce De-
from June 17-20 is expected to gener- audience, attract additional biotech This year, more than 2,200 compa- velopment Agency, California Com-
ate $83 million in economic benefits, investment and bring immediate eco- nies will exhibit, including hundreds munity Colleges, the California Insti-
ranking it second in terms of econom- nomic benefits to the region.” of local organizations, on a floor cov- tute for Regenerative Medicine, and
ic windfall for the region. ering 220,000 square feet of space. local biotech firms Gen-Probe Inc.,
According to the San Diego Con- 1MBOUJOH4FFET That is up from 890 companies using Ceregene Inc. and Genoptix Medical
vention Center Corp., the more than For San Diego’s celebrated biotech 81,700 square feet of exhibition space Laboratory, says Jennifer Landress,
20,000 expected biotech convention hub, the four-day forum will provide back in 2001. vice president of corporate relations
attendees will generate an estimated ample opportunity to showcase in- The conference will have 175 at Biocom.
$34.6 million in direct spending, $1.5 novations in areas such as stem cell breakout sessions, business forums Prominent scientists will use the
million in tax revenues, and generate research and the study of the human and panel discussions. Among this pavilion to make presentations on a
almost 40,000 hotel nights. Only the genome. Additionally, local scientists year’s keynotes are Craig Venter, wide range of topics, including how to
2008 Winter Fancy Foods and Con- will use the panel discussions to voice founder, chairman and president of better understand our genes to delay
fection Show is expected to bring a their concerns, including how to se- the J. Craig Venter Institute; Gover- or prevent disease, bringing research
higher economic benefit to the region cure funding for future innovations nors Arnold Schwarzenegger of Cali- into K-12 classrooms and translating
this year, totaling nearly $100 mil- and protect intellectual property, fornia and Deval Patrick of Massa- stem cell biology to humans.
lion, the corporation reported. with key policymakers, government chusetts; former Governor Jeb Bush On June 18, from 10 a.m. to 1 p.m.,
Jim Greenwood, president and officials and other leading scientists of Florida; and former Secretary of the pavilion will offer a complimen-
chief executive officer of Washington who will come to the convention from State General Colin Powell. tary necklace made of the DNA ex-
D.C.-based BIO, which represents all over the world, says Joe Panetta, tracted from each individual’s cheek,
more than 1,200 biotechnology-re- president and chief executive officer -PDBM4IPXDBTF Biocom said.
lated organizations in the United of Biocom, a San Diego-based bio- Panetta expects at least half of Panetta hopes to draw a crowd for
States, says that both BIO and San technology trade group. Biocom’s 600 member companies to his two panel discussions: a transla-
Diego’s biotech sector have seen tre- “The short-term benefit of having attend the conference. This year’s tional research forum to be held on
mendous growth since the last an- the meeting here is that it will make California pavilion, which represents June 16 from 9 a.m. to 7 p.m. and
nual convention here in 2001 drew it much easier for local companies to Biocom, the state of California, Bay- “Progress on Proposition 71, the Cali-
14,731 visitors. do business and network,” Panetta Bio and TeamCalifornia, will take up fornia Stem Cell Initiative” on June 17
“As one of the leading biotech re- said. “Long-term, as in 2001 … peo- 4,000 square feet of exhibit hall space Please turn to BIO on Page 20
BRINGING PEOPLE
TOGETHER At THOMPSON SEARCH GROUP we are a
family of companies providing top talent for a full
range of Professional Accounting and Financial
business needs. Contact us to conduct a search for
a Permanent Professional. If you need an imme-
diate part time or fulltime project consultant, top
notch Professionals are available in short notice. Call
THOMPSON SEARCH to work with the best
professional resources in San Diego
Typical positions we fill are:

• CFO, VP Finance

• Controllers / Assistant Controllers
• Audit (Internal and External)

• Financial Analyst / Managers
• Financial Planning / Budgeting
• SEC Reporting !
• SOX Compliance
" #

THOMPSON SEARCH delivers Senior level Staffing solutions.
CONTIGENCY SEARCH • RETAINED SEARCH • INTERIM CONSULTANTS • PART TIME PLACEMENTS
At THOMPSON SEARCH we solve your challenges by supplying the best qualified professional to
meet your unique business needs.
Bringing People Together For Over 25 Years

Three Companies One Vision Complete Solution
San Diego’s top firm to find Accounting and Financial Professional Talent
5080 Shoreham Place, #204, San Diego, CA 92122

858-452-1200 • www.thompsonsearch.com
#*04VQQMFNFOU "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM +VOF
BIO
Biomedical Innovation Advances
2008
Nation’s Health Care Status
By James C. Greenwood in the health care system. place. Reaching those levels would be made more efficient and less costly,
In this pivotal election year, Amer- Political leaders are responding to require roughly a 24 percent reduc- with expanded patient access. How-
icans are demanding better, more af- public concerns with a broad range of tion in U.S. drug prices. ever politically popular it may be for
fordable and more accessible health proposals to reduce health care costs, Prescription medicines account for policymakers to go after drug manu-
care. The members of the Biotechnol- many of which tar- about 13 cents of every dollar spent facturers, drugs are simply not the
ogy Industry Organization, which get the cost of pre- on health care in the United States. largest driver of health care costs. Re-
includes companies that have pio- scription drugs. A 24 percent reduction in drug prices duction in that area can never produce
neered hundreds of lifesaving thera- The presidential would save about 2.4 cents out of ev- enough savings to solve the problem.
pies, vaccines and diagnostics, believe candidates of both ery health care dollar, or $69 billion Instead, we should reduce costs by fo-
that continued biomedical innovation parties support per year. cusing on a goal we all share: prevent-
is the nation’s best hope for reducing the government di- However, consider that the total ing and curing disease.
the burden of disease and improving James C. Greenwood rectly negotiating annual research and development
health care and quality of life. drug prices under expenditures of America’s pharma- 3FEVDJOH$ISPOJD%JTFBTF
Americans have come to take qual- Medicare Part D, a departure from the ceutical and biotechnology compa- The real driver of health care costs
ity health care for granted and are current free-market approach in that nies are approximately $55 billion. is chronic disease. Chronic diseases
concerned with paying for it. Up to 40 successful program. They also support European-level pricing would leave are ongoing conditions, such as heart
million people in the United States the re-importation of price-controlled America’s drug discovery companies disease, cancer and diabetes, which
lack health insurance and nearly drugs from Canada and elsewhere. scarce resources for biomedical R&D are often preventable and frequently
50 percent of Americans fear rising Regardless of who becomes president to deliver better and more effective manageable through early detection,
health care or health insurance costs. in January 2009, we will see a signifi- drugs in the future. improved diet, exercise and treat-
The United States spends more on cant effort to transform the nation’s Few would dispute that the Ameri- ment. Chronic diseases are the lead-
health care today than ever before. health care system. can market drives innovation when it ing cause of death and disability in
In 2006 the nation’s total health care comes to life science products and bio- the United States. A minimum 133
spending was $2.1 trillion. This equals $BO1SJDF$POUSPMT8PSL tech drugs in particular. The pricing million Americans, 45 percent of the
16 cents out of every dollar of U.S. eco- The new president will find many and reimbursement available here population, have at least one chronic
nomic production, compared to just willing partners for change in Con- fuel global innovation. Disrupting disease, and chronic diseases are re-
over 7 cents of every dollar in 1970. gress. Based on their voting records, that pipeline of innovative new prod- sponsible for seven out of 10 deaths
Faced with these rising costs, most members of Congress take ucts to make existing drugs cheaper nationwide.
Americans rank health care as one of the position that drug prices in the will gradually undermine the quality Chronic disease places a tremen-
their top domestic concerns, second United States should be closer to the of health care that Americans have dous burden on our health care sys-
only to the economy, and a majority of prices charged in Canada or Europe, come to expect. tem. People with chronic conditions
Americans favor fundamental change where strong price controls are in The health care system needs to Please turn to BIOMEDICAL on Page 10
E
ÀLÞÊ >Ê>ViÊEÊ}iÊ*
7}Ê-ÕÌÃÊÀÊ"ÕÀÊ
iÌÃ
Oceanside
California
biotech by the beach
INTERSTATE
UC Irvine 405
Orange County
INTERSTATE
15
INTERSTATE
5 MiraCosta
College
C AL
76
IFORNIA
Palomar
College
Oceanside C AL
78
IFORNIA
Cal State
7i½Ê7>ÌVÊ9ÕÀÊ >V t Strategic Location
INTERSTATE
5
San Marcos
t Available Land & Buildings INTERSTATE
15
ÀÊÀiÊÌ>ÊÎäÊÞi>ÀÃ]ÊÜiÊ>ÛiÊÀi«ÀiÃiÌi`ÊÌiÊÌ«Ê>iÃÊÊi>ÀÞÊiÛiÀÞÊ
t Great Transportation System
UCSD INTERSTATE
805
>ÀÊ`ÕÃÌÀÞÊÊ>ÜÃÕÌÃÊÀ>}}ÊvÀÊV>ÃÃÊ>VÌÊ>ÌÌÀÕÃÌÊÃÕÌÃÊÌÊ
V«iÝÊÃiVÕÀÌiÃÊV>ÃiÃ°ÊÊ"ÕÀÊ>ÌÌÀiÞÃÊ>ÀiÊ>}ÊÌiÊÃÌÊiÝ«iÀiVi`Ê
INTERSTATE
5
San Diego INTERSTATE
ÌÀ>Ê>ÌÌÀiÞÃÊÊ->Êi}°ÊÊ"ÕÀÊViÌÃÊVÕ`iÊÀÌÕiÊxääÊV«>iÃ]Ê USD

8
SDSU
`ÃâiÊ>`ÊÃ>ÊvÀÃ°ÊÊ7iÊ>ÛiÊÃÕVViÃÃvÕÞÊÌÀi`Ê>ÀÊV>ÃiÃÊÌÊÛiÀ`VÌÊ
IFORNIA
C AL
163
ÊÛ>ÀÕÃÊ`ÕÃÌÀiÃÊ>`Ê«ÀviÃÃÃ]ÊVÕ`}ÊviÊÃViViÃÊV«>iÃ°
www.ci.oceanside.ca.us
email: jmcvey@ci.oceanside.ca.us
Phone: 760-435-3352

BIO 2008
5IF TRVBSFGPPU UXPCVJMEJOH/FYVT6OJWFSTJUZ$JUZ4DJFODF$FOUFSJTDVSSFOUMZVOEFSDPOTUSVDUJPOBUUIFJOUFSTFDUJPOPG*OUFSTUBUFBOE-B+PMMB7JMMBHF%SJWF
The Challenges and Characteristics of

Life Science Real Estate
By Sarah Wager countries. mean that these buildings generally 4. The power grid must be capa-
The life sciences industry, more “The Colliers life sciences group command a much higher price per ble of supplying 25 to 40 watts per
than most industry sectors, requires a has a major presence in each of the square foot than office space. Shell square foot, the appropriate electri-
specialized infrastructure – buildings, life sciences clus- construction costs can range from cal capacity for power and emergency
equipment and personnel – to provide ters and emerg- $175 to $500 per square foot. Tenant power, to meet the augmented HVAC
the foundation for its activities. This ing markets in the improvement costs can range from requirement of a minimum 2 cfm (cu-
infrastructure plays an important United States, Can- $100 to $200 per square foot.” bic feet per minute) per square foot
role, not only in the productivity of ada, Europe and at labs and 1.2 cfm per square foot at
life science personnel, stimulating the Asia, bringing a 4QBDF$POTJEFSBUJPOT support areas, for research data and
best and most creative thinking, but global understand- The technical nature of life sci- scientific analysis tools.
also in enabling and protecting work ing of the develop- ence space and the complexity of the 5. It is essential that vertical space
Tom Mercer
that must be done to create, produce ments driving the systems serving the space demand is available for supplying sufficient air
and deliver new drugs and treatments life sciences industry, a national un- special consideration. There are sig- and removing exhaust fumes, with a
to improve human health. derstanding of the U.S. market and nificant physical characteristics that clear height of 13 feet to 16 feet floor-
“By focusing on the life sciences a local perspective as a major player differentiate life science facilities to-floor for fume hoods and exhaust.
industry, our group is unique,” said in each local market it serves,” said from general commercial properties. Additionally, concentrated equipment
Milt Charbonneau, a vice president Charbonneau. 1. Most lab facilities include a split and work-bench areas in lab buildings
of the Colliers International Life Tom Mercer, a senior vice presi- of 60 percent lab to 40 percent office require heavy loading capacity.
Sciences Real Estate Group. “Our dent of the Colliers International use. Researchers also need common 6. Building adjustments may be
primary goal is to help our clients Life Sciences Group explains that life areas such as lounges and breakout needed to prevent vibrations from
concentrate on research and develop- science space is qualitatively differ- rooms to meet, discuss and collaborate, the equipment and street environ-
ment while we take care of their real ent from office space. in addition to shared support services. ment from affecting sensitive lab ex-
estate needs. We provide innovative “The required structural charac- 2. Special consideration must be periments.
real estate solutions to the industry teristics, strict environmental and given to building services, including 7. Zoning restrictions and other
through a dedicated group of more safety restrictions, coupled with the an evaluation of the chemicals that state and federal regulations can
than 100 professionals in investment hybrid nature of space required by will be stored and transported and inhibit or prevent use changes, the
sales, construction, leasing, facility lab tenants, make new construction how biological waste will be disposed. handling of hazardous materials and
management, finance and develop- highly specialized and an integral 3. Sufficient air conditioning is the ability to locate equipment or sys-
ment.” part of the clinical delivery and sci- critical to life science users and re- tems on the roof of a building.
Colliers International is a lead- entific discovery process,” said Mer- quired ventilation systems, with 90 8. Flexible space design is critical
ing global real estate services com- cer. “The additional amenities and percent to 100 percent fresh air, must to allow growth. Every floor should
pany with more than 290 offices in 61 physical characteristics required be worked into the base building. Please turn to SCIENCE on Page 14

BIO 2008
Oceanside Courts Acclaim as ‘Biotech by the Beach’
By Jane McVey specification buildings; the Pacific CityMark was just entitled a five- ground floor anchored by Harni Su-
Since Oceanside successfully com- Coast Business Park, an AMB project contiguous-block, vertical mixed-use shi, offices on the second floor and
peted for the IDEC Pharmaceuticals under construction; Seagate Corpo- project. The project will have 231 con- four floors of condos; the Wyndham
manufacturing facility, it has actively rate Center, a Rockefeller project; and dos, 48,000 square feet of commercial time-share resort, featuring the new
been pursuing other biotech compa- Oceanside Gateway Business Park, space and a 124-unit hotel or office 333 restaurant by the Cohn Restau-
nies. The Oceanside IDEC campus, a 500,000-square-foot complex with building. SD Malkin is entitled for a rant Group; the Ocean Lofts condo-
which became Biogen Idec, was even- various sized buildings. All of these 384-unit, four-star hotel/time-share miniums; and the Ocean Village ver-
tually bought by Genentech and oper- business parks are accessible by the resort at the beach, and is in the final tical mixed-use project.
ates today in a 520,000-square-foot new North County Transit District’s stages of approval with the Coastal All of these projects and others are
facility in Ocean Ranch Corporate Sprinter line that runs on the south Commission. adjacent not only to the beach, but to
Center. side of Oceanside Boulevard. Downtown Oceanside is becoming the Amtrak/Coaster/Sprinter station
Oceanside, calling itself “Biotech Oceanside’s “Biotech by the Beach” a hip, urban tourist village thanks to downtown – one of the busiest trans-
by the Beach,” touts its large lots for tagline also plays off all the new de- new parking garages; the Oceanside portation hubs in the state. Oceans-
new and expanding biotech compa- velopment in the city’s downtown. Terraces project, with retail on the Please turn to OCEANSIDE on Page 7
nies; superior access, with locations
accessible by a new light-rail line
connecting Interstate 5 and Inter-
state 15; and most importantly, its
partnership with MiraCosta College.
With industry support, the college
was instrumental in creating the Mi-
raCosta Biotechnology Center, which
now trains the biotech work force for
Genentech and other local biotech
companies. These include Nitto Den-
ko America Inc., which does research
and development; Andergene, a DNA
lab and research facility; and Stem
Cell International, a biotech research
firm.
“The MiraCosta Biotechnology
Center was made possible through
the partnership between IDEC; DPR,
the contractor for the buildings; Mc-
Graw Baldwin, the architect; ISPE,
the International Society of Pharma-
ceutical Engineers; and many others
in the industry,” said Ric Mathews,
dean of math and sciences for the
college. “Since its inception, we have
trained and placed many technicians
for the industry.”
#SJOHJOHJUUP#*0
Oceanside is taking its search to
the BIO International Convention in
San Diego, June 17-20, and will set
up shop in the California pavilion.
In addition to showcasing its busi-
ness parks, Oceanside will tout the
experience of city staff in entitling,
permitting and inspecting highly
sophisticated biotech facilities. Dur-
ing construction of the Genentech
(originally IDEC) campus, Oceanside
dedicated a building inspector on-site
to make the inspection and approval
process as efficient as possible.
According to former IDEC contact
Phil Schneider, “Oceanside’s commit-
ment and service was fantastic, and
we couldn’t have kept on schedule
without their help.”
Oceanside was chosen for its pro-
active zoning and building height
flexibility; proximity to major metro-
politan areas; the Sprinter line; and
the city’s willingness to accelerate
the building process.
/FX%FWFMPQNFOU
Available properties ideal for the
biotech industry include the Ocean
Ranch Corporate Center, with several
large lots remaining and a few large
BIO 2008
Life Sciences in British Columbia:
A Passion for Success
Submitted by the British Colum- effective steps to create a supportive Newer players are also showing in 2007.
bia Ministry of Economic Devel- low-cost business climate capable of great promise in British Columbia’s The BC Cancer Agency is one
opment fostering and sustaining biotech suc- life sciences and biotech corporate of the top cancer care and research
Life sciences are flourishing in cess. community. Companies attracting centers in the world, achieving the
British Columbia, Canada’s fastest- attention include: Cardiome Pharma best patient outcomes in Canada.
growing life sciences center and home $FMFCSBUJOH4VDDFTT4UPSJFT Corp., a product-focused cardiovas- Completed in 2004, the BC Cancer
to the seventh largest concentration British Columbia’s advantages cular drug development company; Agency’s Research Centre has more
of biotech businesses in all of North have translated into a track record of Medical Ventures Corp., a medical than 231,000 square feet of capacity
America. stellar successes in life sciences and device company; Xenon Pharmaceu- to support up to 600 scientific and
More than 175 life sciences com- biotechnology. For its age and size, ticals Inc., a privately held drug de- medical personnel.
panies representing biopharmaceu- British Columbia’s life sciences clus- velopment company; Lignol Energy
ticals, medical devices, bioproducts, ter has seen significant commercial Corporation, LifeSciences British %FWFMPQJOH4VQFSJPS5BMFOU
bioinformatics, marine biotech, for- success and earned high returns on Columbia’s 2008 Emerging Company British Columbia has enjoyed suc-
est biotech and agricultural biotech, investments. It is now home to four of the Year, specializing in biorefinery cess in attracting skilled workers for
among other bio-specialties, are do- of the top 10 biotech companies in technology; and Neuromed Pharma- technology sectors, including biotech-
ing business in British Columbia. Canada. ceuticals, developer of drugs to treat nology, and for investing in a strong
Together they employ about 2,700 The province’s first three com- chronic pain. post-secondary education system to
people and earn annual revenues of mercially successful biopharmaceu- develop home-grown talent.
approximately $800 million. As a re- tical companies, QLT Inc., Angiotech /VSUVSJOHB$VMUVSFPG Almost 40,000 skilled workers
sult, this province has developed one Pharmaceuticals Inc. and Aspreva 8PSME$MBTT4DJFODF immigrated to British Columbia be-
of the most vibrant life sciences in- Pharmaceuticals Inc., were among The Government of British Co- tween 2001 and 2005. The provincial
dustries in the world. the first life sciences companies in the lumbia has invested more than $2 government introduced a program to
British Columbia’s success in life world to achieve profitability. In addi- billion in research, infrastructure accelerate entry of skilled workers
sciences didn’t happen by accident. tion to these industry leaders, British and institutions, creating an envi- into their fields of expertise.
There are solid reasons why life sci- Columbia-based companies ID Bio- ronment where world-class science is British Columbia’s booming econ-
ences companies find British Colum- medical and AnorMED attracted in- conducted at institutions, such as the omy, welcoming and diverse cultural
bia, Canada’s Pacific Gateway, a great ternational attention and close to $2 University of British Columbia. UBC mosaic, and outstanding quality of life
place to establish roots, grow and billion in investment to the province ranked first in Canada and ninth in make the province a global destina-
prosper. Recognizing the importance through their acquisitions by Glaxo- North America in registered patents. tion for people across the professions.
of a strong technology sector, the pro- SmithKline and Genzyme Corpora- Annual research funding at UBC ex- As a result, the province has devel-
vincial government has taken bold, tion, respectively. ceeds $400 million. oped a highly educated, multilingual
UBC’s late Nobel Laureate in work force. Two-thirds of technology
Chemistry, Dr. Michael Smith, proved workers in British Columbia have at
a catalyst for the tremendous increase least one college or university degree,

in research activity in the province
over the last decade. Organizations
representing a deep talent pool for
life sciences companies and research

such as Genome British Columbia institutions.
invest in and manage large-scale ge- By 2010, the province of British
nomics research and technology proj- Columbia will have funded more than
ects. The Michael Smith Foundation 30,000 additional places in its 25 pub-
for Health Research, established in lic post-secondary institutions. Some
2001 by the provincial government, schools in British Columbia are cre-
is building capacity for excellence in ating programs that focus on technol-
clinical, biomedical, health services ogy, including biotech. For example,
and population health research. UBC and the British Columbia Insti-
Simon Fraser University, the Uni- tute of Technology jointly provide an
versity of Victoria, the University of undergraduate degree program dedi-
Northern British Columbia, as well cated to biotechnology. SFU offers a
as leading health care facilities such Masters of Technology MBA, includ-
as the BC Cancer Agency, the Van- ing a specialization in biotechnology.
couver Coastal Health Research In-
stitute, Vancouver General Hospital #VJMEJOHB4VQQPSUJWF$MJNBUF
and Providence Health Care are also GPS#JPUFDI#VTJOFTT
strong centers of life sciences re- Determined to create a supportive,
search. low-cost business climate, business
"#$$$ %

SFU is a leader in Canada and tax burdens in British Columbia are

North America for the number of among the lowest in North America.

companies created per $1 million in Since 2001, the province has imple-
& '() ! *
)

research. To date, more than 70 spin- mented 31 tax relief measures, cut
+!, off companies have been established corporate income tax by 21 percent,
% *!
to commercialize technologies devel- and cut personal income tax by 32.5
oped by SFU researchers. percent. In addition, the province has
* + Researchers at the UVic are mak- granted generous tax credits for re-
%- *!.% ! ! ing major contributions in the life search and development investment

%- /0123 42562 sciences and related fields, includ- and venture capital investment.The
! ! ing bio-ocean sciences, genetics and

proteomics, forest and plant biology,
provincial government established
the International Financial Centre
neuro and biomedical sciences, and to position British Columbia as a
climate modeling. UVic faculty made top-tier destination for international

major contributions to the Intergov- financial transactions and corporate
ernmental Panel on Climate Change, head offices. Revenues earned from
recipient of a joint Nobel Peace Prize Continued on the next page

BIO 2008
Selecting the Right Executive Search Firm
By Judy Thompson fice? paper. This includes the firm’s repu- department, where applicable?
When you limit your hiring prac-  How expansive is the firm’s net- tation with its candidates and clients. Most importantly, look for an ex-
tices to employees actively promot- work? How, and how often, does it Are phone calls returned quickly? Is ecutive search firm that will be genu-
ing their résumé, or to those found stay in touch with its network of con- the firm endorsed by satisfied clients inely invested in your company and
through answered ads, you may tacts? who are similar to your company in your repeat business.
overlook candidates who could be an  In order to adeptly present your industry or size?
optimum fit for the position and the company in its most positive but real- Once you meet a prospective agen- "OBEWFSUPSJBMTVCNJUUFECZ5IPNQ
company’s culture. Even if you at- istic light, does the firm have a policy cy, take note of how well both com- TPO4FBSDI(SPVQ+VEZ5IPNQTPOJT
tract 100 or more applicants in your of visiting each client to understand panies interact. Is the firm easily ac- QSFTJEFOU PG UIF DPMMFDUJWF DPNQBOJFT
own search, their caliber is limited to the company’s culture and needs pri- cessible? Is there a strong chemistry XIJDINBLFVQUIF5IPNQTPO4FBSDI
those actively seeking new positions. or to contacting top talent? based on mutual respect and trust? (SPVQ 'PS NPSF JOGPSNBUJPO QMFBTF
A skilled executive search firm  Does the firm have adequate Is the firm willing to coordinate its DBMM
PS WJTJU XXX
understands your company’s culture time to devote to your assignment? efforts with your human resources UIPNQTPOTFBSDIDPN
and the position for which you are Does it use research assistants? How
recruiting, and then approaches the does it track the careers of the top
market’s finest candidates, including candidates in the field?
those who are not currently seeking  Are candidate references thor-
new employment. Especially when ough and in writing?
the opening is a key position, con-  What are the firm’s guarantees?
sider selecting a quality firm to work  How many searches will the firm
with you to fill the search. conduct simultaneously? Approxi-
Once you have decided to go in this mately how long should the search
direction, there are important consid- take?
erations when selecting a firm. Here  What networking organizations
are some questions to ask before en-
gaging the services of an executive
does it attend to stay in touch with
top talent?

search firm:  Will the firm’s representatives
 How long has the company been
in business and what is its accumu-
meet with you personally after each
placement to ensure your satisfaction?

lated knowledge of the marketplace?
 What is the tenure length of the
While some of these questions are
straightforward, there are other as-

most experienced person in the of- pects to consider that may not be on
Life: This drops to 15 percent by 2012.

These investment-friendly measures
Continued from the preceding page support a strong financial infrastruc-
patents in the field of life sciences and ture that helps attract and sustain in-
clean energy enjoy tax exemption. vestment in technology, including life
In addition to British Columbia’s sciences companies. When it comes to
tax credit venture capital programs, attracting investment capital, noth-
the provincial government recently ing sells like success. British Colum-
committed $90 million, over three bia is one of the top five jurisdictions
years, to the B.C. Renaissance Capi- in North America for generating val-
tal Fund to help provide follow on ue from research and development.
financing for innovative businesses. Life sciences researchers, insti-
The BCRCF will invest in six top-tier tutions and businesses have taken
venture capital funds that, in turn, firm root in British Columbia’s fertile
will invest in promising technology environment. With investment, re-
companies based in British Columbia search and education support, and a
and elsewhere. The BCRCF’s $90 mil- skilled, diverse work force, the future
lion can leverage up to $400 million will continue to offer exciting growth
from institutional investors. Recent opportunities for life sciences in Brit-
federal and provincial budget mea- ish Columbia.
sures include: eliminating withhold- "O BEWFSUPSJBM TVCNJUUFE CZ UIF
ing taxes on international financing, #SJUJTI $PMVNCJB .JOJTUSZ PG &DP
eliminating all capital taxes on finan- OPNJD %FWFMPQNFOU 'PS NPSF JOGPS
cial institutions by 2010, and allow- NBUJPO QMFBTFWJTJUXXXHPWCDDB
ing multinationals to report in their
functional currency, which will sim-
plify financial statement reporting by
multinational companies doing busi-
Oceanside:
ness in Canada. British Columbia’s Continued from Page 5
current corporate tax rate, federal ide is banking on access, available
and provincial combined, is the sec- land, an established biotech presence
ond lowest in North America at 30.5 and strong college partnerships as it
percent, and will drop further to 29 pitches the city to other biotech firms
percent in 2009, and 26.5 by 2011. that are looking for expansion loca-
Furthermore, eligible companies reg- tions.
istered with the province’s Interna- .JOU[ -FWJO $PIO 'FSSJT (MPWTLZBOE1PQFP 1$
tional Financial Centre are exempt "OBEWFSUPSJBMTVCNJUUFECZUIF$JUZ #PTUPO]8BTIJOHUPO]/FX:PSL]4UBNGPSE]-PT"OHFMFT]1BMP"MUP]4BO%JFHP]-POEPO
from provincial income taxes; conse- PG 0DFBOTJEF +BOF .D7FZ JT XJUI UIF XXXNJOU[DPN
quently IFC companies currently pay $JUZPG0DFBOTJEF'PSNPSFJOGPSNBUJPO
only the federal rate of 19.5 percent. QMFBTFWJTJUXXXDJPDFBOTJEFDBVT
BIO 2008
Arizona’s BIOZONA:
Business-Friendly and Bio-Ready
By Jaye O’Donnell lational Genomics Research Insti-
For companies seeking to relocate tute and Arizona State University’s
or expand operations, Arizona has Biodesign Institute to establish the
always been a viable option for es- Partnership for Personalized Medi-
tablishing a western U.S. presence. cine, an endeavor of global scope
Now more than ever, Arizona brings that will use the latest advances in
together all the key elements for proteomics to develop, validate and
success in a global economy: access apply new molecular diagnostics to
to markets, talent, technology and a improve health outcomes and reduce
location that offers operating cost ad- health care costs.
vantages. • ASU’s Biodesign Institute is
Knowledge-based businesses look Greater Phoenix’s single largest gen-
to expand in high-growth areas, and erator of federal biomedical research
Arizona has long been one of the fast- funding, helping form more than 200
est-growing states in the country. It collaborations with clinical, industrial
is complemented with excellent pri- and research organizations. Partner-
vate and public universities and the ships include collaborating with BP
largest community college system in Amoco PLC to develop cyanobacteria
the country. Arizona boasts one of the 1BQBHP(BUFXBZ$FOUFSJTBOFXTUBUFPGUIFBSUSFTFBSDIGBDJMJUZ5IF TRVBSFGPPU TFWFO optimized to produce high-energy fat
TUPSZCVJMEJOHJT4JMWFS-&&%$4DFSUJàFE
most attractive work forces in the for biodiesel fuel and working with
nation, and the bioscience work force firms, and for 2007, private invest- just the last few years, Arizona’s pri- Motorola to improve the detection of
here continues to grow. ment in biotech startups may hit a vate and public partnerships have es- explosives.
“Job growth in the biosciences has five-year high.” tablished the state as a leader in can- • BIO5 Institute at the University
been strong in Arizona since 2002, far cer therapeutics, bioengineering and of Arizona brings together top UA
outpacing nationwide growth, and 1BSUOFSTIJQT4QVS*OOPWBUJPO neurological sciences. The following scientists from five disciplines: ag-
bioscience jobs in Arizona pay signifi- Arizona has a strong reputation are examples of recent collaborations riculture, medicine, pharmacy, basic
cantly better than jobs in the overall in the established industries of aero- within the bioscience industry. science and engineering. In January,
private sector,” said Walt Plosila of space, electronics, optics and semicon- • Nobel Laureate Lee Hartwell, the National Science Foundation re-
Cleveland-based Battelle. “Addition- ductors. It is also considered a growing president and director of Seattle’s warded BIO5’s assembly of ingenuity
ally, the state has shown impressive force in environmental technologies, Fred Hutchinson Cancer Research with a $50 million grant to establish
growth in the number of bioscience nanotechnology and life sciences. In Center, has joined with the Trans- Please turn to ARIZONA on Page 24
Manitoba: The Heart of Canada’s

Life Sciences Industry
By Douglas G. McCartney This network promotes Manitoba’s developments and validation of new  Industrial Technology Centre
One of your company’s most sig- research capabilities and strategic hyperimmune and recombinant ther- – A special operating agency of Mani-
nificant discoveries could be capital- partnerships to build on the prov- apeutic products. Cangene’s recent toba Science, Technology, Energy and
izing on the industry-related knowl- ince’s flourishing functional foods successes include the development of Mines, ITC operates the Virtual Real-
edge and infrastructure potential in and nutraceutical sector. It repre- drugs for use in liver transplants and ity Centre in Winnipeg. This unique
Manitoba, Canada. sents the outstanding work of three cancer care. facility provides easy access to the
This centrally located province key facilities: the Canadian Centre  Composites Innovation Centre most advanced 3-D visualization
is home to one of the fastest grow- for Agri-food Research in Health and – A non-profit organization, CIC uses tools and expertise. The VRC allows
ing biotechnology and life science Medicine; the Food Development composite materials and technologies biotech companies to visualize com-
clusters in Canada. The federal and Centre; and the Richardson Centre to support and stimulate economic plex datasets within a virtual space
provincial governments continue to for Functional Foods and Nutraceu- growth through innovative research. model or immersive environment.
encourage the growth of knowledge- ticals. Successfully guiding potential It develops new products and process-  Life Sciences Association of
based industries and strongly sup- products, from concept to market, is es, and commercializes in the areas Manitoba – Since 1990, this associa-
port technology commercialization. at the heart of MAHRN’s work. of aerospace, biomaterials, civil infra- tion has represented and provided in-
This strategy has created a thriv- structure and ground transportation. dustry-specific training to more than
ing biotechnology industry, one that #*00QQPSUVOJUJFT CIC also provides many value-added 100 member companies in the life sci-
is constantly striving toward even Among the innovators contribut- services, including project planning ences industry. The training has in-
greater scientific achievements. ing to Manitoba’s biotechnology and and management, technology consul- cluded the biotech and pharmaceuti-
Manitoba’s life sciences industry life sciences that will be participat- tation, business planning, communi- cal sectors, medical assistive devices
and diverse biotechnology sector of- ing in the Canadian pavilion at this cation, and education services. and health research.
fer promising opportunities for stra- year’s BIO International Convention  Genome Prairie – This company  Medicure Inc. – This Winnipeg-
tegic partnerships in such diverse are: is a recognized leader in the sup- based, cardiovascular-focused, phar-
areas as health-enhancing functional  Cangene Corp. – This Winni- port and management of large-scale maceutical company markets the
food and nutraceutical development, peg-based pharmaceutical company genomics and proteomics research acute care drug, Aggrastat, and is
biomedical innovations, and biocom- is a world leader in developing and projects in western Canada. Genome one of Canada’s only pharmaceutical
posite material production. Potential manufacturing countermeasures Prairie and its strategic partnerships companies independently market-
collaborations abound and may be against crucial biological infectious have supported more than $120 mil- ing pharmaceuticals in the U.S. The
just what you need to turn your good disease, such as smallpox, anthrax lion in research activity in plant, company also offers preclinical and
idea into a great reality. and other bioterrorism agents. Can- animal and human genomics, bioin- clinical stage drug development pro-
Take the Manitoba Agri-Health gene’s research and development formatics, instrumentation develop- grams.
Research Network, for example. facility is the center of leading edge ment and bioethics. Please turn to MANITOBA on Page 9

BIO 2008
New Reproductive Technologies Show
Kinship is a Bond Beyond Nature
By Dylan O. Malagrino kinship bonds are created in novel With assisted reproduction, the natu- constitutional right to marry in Cali-
Since the first ultrasound 50 years ways, as through technology, the rec- ral creation of kinship has been denat- fornia, and by hearing arguments in
ago, the medicalization of reproduction onciliation of our notions is that we uralized and is reconstituted as part North Coast Women’s Care Medical Group
has reduced procreation to a fertility must now see our- of the social. Nature as the basis for v. Superior Court (Benitez), S142892, a
question of whether medicalized un- selves differently kinship is becoming a matter of choice case in which San Diego doctors de-
derstandings of our bodies can foster and view kinship in a consumer society. The effect of as- nied a lesbian couple fertility treat-
natural procreation for the infertile. as a social con- sisted reproduction is that kinship re- ments because the doctors objected
Yet, new reproductive technologies in- struct not limited lations, and more specifically parent- to same-sex couples raising children.
cluding in vitro fertilization, intracy- to that which is hood itself, can now be perceived as Contributing to this discourse, there
toplasmic injections and even bioengi- only natural. Con- either socially constructed or natural. must be radical shifts in traditional
neered gemetes, such as female sperm Dylan O. Malagrino trary to claims that Relatedness is a central concern understandings of “kinship” because
and male ova, are changing decades of reproductive tech- for some legal scholars, not only from of widespread use and availability of
biological assumptions about reproduc- nologies are racing ahead of society’s normative perspectives on kinship reproductive technologies.
tion as natural to human existence. If perceived morality, innumerable and what it means to have kin, but
children are not genetically related to possibilities for reproduction have also in juridical literature on rights "O BEWFSUPSJBM TVCNJUUFE CZ ,JSCZ
their parents, are they really kin? The emerged to fit the choices and chal- and obligations to the kin in our lin- /PPOBO-BODF)PHF--1%ZMBO0
answer is yes, if we recognize kinship lenges posed by society’s new medical eages. Recently, the California Su- .BMBHSJOP JT BO BUUPSOFZ XJUI ,JSCZ
as a social construct. and scientific understandings of the preme Court rekindled a vibrant dis- /PPOBO-BODF)PHF--1'PSNPSF
Most Americans see kinship as ways in which we can procreate. course on relatedness, family-making JOGPSNBUJPOPOUIFJEFBTJOUIJTBEWFS
natural because of their notions that Employing technologies as part of and human reproduction by ruling UPSJBMPSPOUIFQSBDUJDFTPG,JSCZ/PPO
it is physical, genealogical and re- reproduction processes undeniably in In re Marriage Cases, 2008 DJDAR BO -BODF )PHF --1 QMFBTF DPOUBDU
quires transubstantiality, but when changes the way we see ourselves. 7079, that same-sex couples have a .BMBHSJOPBUENBMBHSJOP!LOMIDPN
Supporting the Global Life Sciences Sector

By Raymond D. King fering or Reverse Take-Over, compa- economy, and continues to support 155 years and intends to be a part of
In his book “Good to Great,” Jim nies can also take advantage of the the sector’s long-term financing re- their future.
Collins wrote “Great companies Capital Pool Company program. This quirements.
triumph over time and long-term unique listing opportunity brings a By building on current strengths, "O BEWFSUPSJBM TVCNJUUFE CZ 549
sustained performance can be engi- seasoned management team with both exchanges continue to work with (SPVQ 3BZNPOE % ,JOH JT TFOJPS
neered into the DNA of an enterprise capital together with a private com- life sciences companies from around NBOBHFS PG HMPCBM JOEVTUSJBM TFDUPS
from the very beginning.” pany in need of funding and manage- the world to help engineer success CVTJOFTTEFWFMPQNFOUBU549(SPVQ
TSX Group offers international ment expertise. into their DNA. TSX Group has been 'PSNPSFJOGPSNBUJPO QMFBTFDPOUBDU
life science companies access to North helping listed companies make ad- IJN BU
PS SBZNPOE
American capital pools that will help 5BLJOHUIF/FYU4UFQ vances in life sciences for more than LJOH!UTYDPN PSWJTJUXXXUTYDPN
engineer success into your company’s Toronto Stock Exchange is the
DNA. TSX Group is comprised of ju- world’s seventh largest stock ex-
nior board, TSX Venture Exchange, change and the third largest stock
and senior board, Toronto Stock Ex-
change. Together, TSX Group serves
exchange in North America. TSX
provides listed life science compa- Manitoba: Manitoba is prepared to further
develop these burgeoning sectors by
life science companies from concep- nies with a dynamic market to access Continued from Page 8 providing incentives for startup com-
tualization through to commercial- global capital.  Red River College – Manitoba’s panies interested in establishing new
ization. TSX recognizes that research and largest community college, RRC of- businesses in the province’s remark-
TSX Group’s life science sector has development intensive life science fers more than 110 education and ably cost-effective environment. Man-
grown significantly over the past de- companies must sustain their R&D training programs taught with an itoba’s strategic location, at the cen-
cade, and now includes 140 companies initiatives with significant capital applied focus to ensure students have ter of Canada, makes it a key entry
with total market capitalization of al- infusions to support long-term devel- the skills required to succeed in the point into the Mid-Continent Trade
most $19 billion. As of December 31, opment cycles. The R&D listing cri- industry. In the life sciences and bio- Corridor, giving the province easy ac-
2007, more than $1 billion had been teria therefore focuses on evidence of technology sector, programs empha- cess to a North American market of
raised for companies in this space. In adequate financing and management size quality assurance and control, more than 100 million people.
total, 4.6 billion shares of life science expertise to carry the company for- pharmaceutical manufacturing and The knowledge base, infrastruc-
companies were traded on our two ward with its intended development technical lab skills. The latter are de- ture, business climate, major market
exchanges, having a traded value of program. signed to meet Canadian, American access – it’s all here in the great Ca-
more than $16.5 billion. A TSX listing can offer several and European Union standards. Cus- nadian heartland. Discover the full
clear advantages to life sciences com- tomized training services are also range of possibilities by visiting the
&BSMZ4UBHF panies: available. Manitoba section of the Canadian pa-
$PNQBOJFT.PWF6Q  Access to capital for companies  University of Manitoba’s Technol- vilion at this year’s BIO convention.
As Canada’s national exchange for at early and later stages of growth. ogy Transfer Office – The TTO offers It could well be your next step toward
venture class securities, TSX Venture  Opportunity to access North a range of professional services for bioscientific success.
Exchange provides early-stage life American capital pools. faculty researchers, students and the
science companies with the oppor-  Access to sector- and index-based technology community through inno- "OBEWFSUPSJBMTVCNJUUFECZ.BOJ
tunity to gain a solid foothold in the institutional investors. vative programs in the province and UPCB4DJFODF 5FDIOPMPHZ &OFSHZBOE
North American public capital mar-  Greater analyst visibility and beyond. Its motivated team of scien- .JOFT %PVHMBT ( .D$BSUOFZ JT UIF
kets, and the potential to work to- coverage. tists and corporate development pro- EJSFDUPSPG.BOJUPCB45&.TTDJFODF
wards a graduation to Toronto Stock  Lower costs of going public com- fessionals can help take your product JOOPWBUJPO BOE CVTJOFTT EFWFMPQ
Exchange – Canada’s senior equities pared to the U.S. market. from the lab to the world market, as NFOUEJWJTJPO'PSNPSFJOGPSNBUJPO
marketplace. TSX Group recognizes the im- it has with other successful products QMFBTF WJTJU XXXNBOJUPCBMJGFTDJFOD
In addition to traditional listing portance of the life sciences sector the global sales volume of which now FTDB PS FNBJM MJGFTDJFODFTJORVJSFT!
vehicles such as an Initial Public Of- to the North American and global exceed $100 million. HPWNCDB
BIO 2008
Biomedical: contributions to reducing disease be- and reduce the financial and societal celerating and exciting pace. Our in-
cause they already have. With more burden of disease as never before. dustry has been quite successful at
Continued from Page 3 than 200 biologic medicines and vac- But realizing the life-saving benefits attracting both venture capital and
are the most frequent users of health cines already available, innovators of groundbreaking new therapies will investment from the public markets.
care, accounting for 81 percent of have a long and growing track record require an economic and policy envi- What our companies need to succeed
hospital admissions, 91 percent of of saving lives and reducing the cost ronment that encourages continued is a policy environment that supports
prescriptions filled and 76 percent of of treating disease. investment in innovation. our efforts.
physician visits. As a result, 75 cents More than 400 biotechnology med- The majority of BIO’s member We need to ensure that policy-
of every health care dollar goes to the icines are in development including companies are startup or emerg- makers who want the miracles that
treatment of chronic disease. That is more than 200 treatments for cancer ing companies still developing their biotechnology companies are devel-
about $1.5 trillion out of the nation’s and related conditions, more than first products and dependant upon oping support increased funding for
$2.1 trillion in health care spending. 20 for cardiovascular disease and 15 outside investors for funding. Of the primary research and enact policies
If the incidence of chronic disease for diabetes and related conditions. many promising ideas our industry that encourage and reward the in-
in the United States could be reduced These innovative treatments include generates, only a small handful re- novation necessary to translate that
by just 10 percent, we would save monoclonal antibodies to treat asth- sult in new FDA-approved therapies. research into lifesaving products for
about $150 billion a year in treat- ma, Crohn’s disease and lupus; thera- Biotech investors are willing to take patients.
ment and other costs. That is more peutic vaccines for AIDS; and recom- these risks knowing that the success- We must fully fund the National
than double the short-term savings binant protein to treat autoimmune ful therapies can pay for the ones that Institutes of Health and the Food
we might get from dropping U.S. drug disorders. didn’t pan out and also fund the next and Drug Administration. We need a
pricing to European levels, without round of research to develop the next sound pathway for follow-on biologics
reducing the resources needed for the
)PQFPOUIF)PSJ[PO generation of lifesaving advances. that enables competition while main-
New biomedical technologies on taining the incentives to create new
R&D of better cures for the future.
the horizon are even more promis- 'JHIU%JTFBTF /PU$VSFT medicines. We need a patent system
*OOPWBUJPO4BWFT-JWFT ing. We are moving towards an era of BIO’s mission is to help maintain that continues to encourage and re-
Biotechnology innovation can play tissue engineering in which we will an environment that will enable our ward innovation. We also need poli-
a critical role in reducing chronic be able to grow new organs match- companies to follow the path of innova- cies that help reduce the cost of new
disease. U.S. companies are developing our own DNA, using stem cell tion toward a better health care system drug development.
ing the tools needed to not only treat technology. Gene silencing, or RNA and reduced chronic disease. We will The brilliant scientists around the
many diseases, but also to predict, interference, will enable us to switch continue to help policymakers under- world who have dedicated their lives
preempt and prevent them long be- specific genes on or off to prevent or stand that we cannot regulate our way to eradicating disease will succeed
fore symptoms appear. In the coming cure diseases. Pharmacogenomics is to a better health care system. That if they have the resources and if we
decade, people can have their indi- helping those in the industry better approach may make for good political make the choice as a nation to fight
vidual genomes screened for disease understand why certain drugs work sound bites and even offer temporary the disease, not the cure.
risks so that physicians can help pa- well for some patients, but not for satisfaction to a public frustration with
tients develop lifetime plans of health others, so that doctor’s can choose the health care costs, but if we as a nation "O BSUJDMF TVCNJUUFE CZ UIF #JPUFDI
maintenance based on each person’s right drug at the right dose for the take that route, we will destroy the OPMPHZ*OEVTUSZ0SHBOJ[BUJPO+BNFT$
unique genetic profile. right patient. hope for better cures tomorrow. (SFFOXPPEJTUIFQSFTJEFOUBOEDIJFGFY
Biotechnology innovators are Continuing biomedical innovation There is a right path. The science FDVUJWFPGmDFSPG#*0'PSNPSFJOGPSNB
confident they can make dramatic will alleviate more human suffering of biotechnology is moving at an ac- UJPO QMFBTFWJTJUXXXCJPPSH

From toxicology to manufacturing,
Indiana links discovery and development
Change brings opportunity. As the pharmaceutical and biotechnology Building on that platform, a new initiative has been created and
industries face a series of convergent pressures, strategic utilization developed together with corporate, academic and workforce partners,
of third party vendors to perform essential, but non-core functions and BioCrossroads, Indiana’s initiative to grow the life sciences, to
is increasing at unprecedented rates. The contract service providers advance Indiana’s drug development resources. The BioCrossroadsLINX
that serve as partners in this emerging “networked” model of drug (www.biocrossroadslinx.com) effort will make connections between
development are experiencing growth rates of 14 – 16% industry Indiana’s academic institutions and contract service providers and
wide and in excess of 20% in certain service segments with an other biotechnology discovery centers across the United States, such
overall value of approximately $14 billion. As these trends continue, as San Diego, encouraging regional collaborations and educational and
regions that are already rich with talent and resources serving workforce development programs that capitalize on – and advance –
biopharmaceutical development will be able to further capitalize Indiana’s strengths in drug development and manufacturing.
on existing assets and develop the increased service offerings that
the market is demanding. From formulation to toxicology to pharmacokinetics to central lab
services to manufacturing and 112 other service capabilities within
In the present environment, fully integrated pharmaceutical the drug development continuum, Indiana’s strong scientific and en-
and biotechnology companies (FIPCOs) need to become more trepreneurial spirit helps develop the drugs that improve patients’
nimble and flexible FIPNETS (fully integrated pharmaceutical lives around the world.
networks) by increasing focus on core competencies while
looking to outside service providers and strategic partners for The biotech and pharmaceutical industries may be able to get their life-
assistance in developing, validating and bringing products saving products to patients faster and less expensively by embracing
to market through a network of business relationships. The unique solutions such as regional collaborations. Biotechnology is a
result also spreads the risk of innovation through variable true American competitive strength and collaborative efforts, among
cost contracting. both companies and regions, will lead to improved competitiveness and
the ability to deliver innovation in a global economy.
No need to turn any farther than the middle of the U.S. Indiana
COMPANY ACTIVITY EMPLOYEES
is home to a strong concentration of drug development and
Anaclim CRO 25
manufacturing capabilities, and the right people to help them
AIT Laboratories Toxicology 170
expand as the industry turns to these expert-intensive, cost- Aledo Consulting Market Research 8
effective outsourced services. Indiana has more than 40 contract Anson Group FDA Consulting 12
Aptuit (SSCI) CRO 100
service providers, and their 6,300 people are already doing work BASI CRO 300
for everyone from the top ten pharma companies to large and Baxter Biopharma Solutions Contract Mfg 825
small biotechs to single researchers trying to develop a promising BioConvergence Contract Dvlpmt 27
BioStorage Technologies Cold Storage 50
molecule. Most are expanding their facilities, their capabilities, and Bristol Myers Nutritionals* Dry/wet products Mfg 700
their workforce — providing America’s biotech and pharmaceutical Bristol Myers Pharma* Solid dose Mfg 300
Chao Center for Contract Mfg. Contract Mfg 21
industries with specialized and sophisticated services.
Chemigen CRO 7
Commissioning Agents Regulatory Compliance 140
Concentrics Research CRO 30
Actually, Indiana may be the birthplace for such activities. Cook Biotech* Tissue Mfg 100
Cook Pharmica Contract Mfg 220
Approximately 25 years ago, a centralized method for Covance CRO 850
DCL CRO 200
efficiently and accurately collecting and reporting data
Elona Biotech Mfg 14
from clinical trials did not exist. Enzon Contract Mfg 150
Exaromed Market Research 14
G&S Research Market Research 45
All major pharmaceutical companies housed these central laboratory IN Institute for Biomedical Imaging CRO 70
IU Vector Production Facility Biotech Mfg 13
functions in house, but there were no industry standards to ensure
JLM Pharmatech Contract Mfg 40
efficient access and accuracy of data. As this need was identified as KP Pharma Contract Mfg 20
a standardized, scalable business function, Indiana resources were Krauter Solutions Storage & Logistics 15
Lilly - Clinton** Dry products 200
leveraged to open the world’s first central laboratory in Indianapolis Lilly - LTC North** Biotech Mfg 1500
under the name SciCor – today, the Central Laboratory division of Lilly - Tippecanoe** Bulk API; scale-up 700
Covance, Inc. At the time, they were the only company that could Med Institute FDA Consulting 175
MICR CRO 18
report timely clinical data (within 48 hours) using the same clinical Monarch Life Sciences CRO 18
trial methodology, with an error rate of less than 2%. SciCor/ OBS Medical CRO 15
Safis Solutions FDA Consulting 30
Covance is now the industry standard for what has become a 100%
Seradyn (Thermo Fisher Scientific) Reagent Mfg 125
outsourced market. SCHWARZ Pharma (UCB) Contract Mfg 360
Sentry Logistics Cold Storage 30
Stanbio Biotech Mfg 12
Vesta Pharma Contract Mfg 25
7,678
*Vertically Integrated
**Excludes Lilly Corp HQ/R&D/G&A

Tempe biotech goes green
By Ale
Alex Smith
As a the need for both a sustainable environmental and economic At the juncture of downtown Tempe and downtown Phoenix sits
policies become more important to biotechnology businesses, the city the newly completed Papago Gateway Center. This state-of-the-art
of Tempe, Arizona is showing itself to be ahead of the pack on both research facility, designed by SmithGroup Inc., features an exterior
fronts. louver system for maximum shade protection. A development of
Chesnut Properties LLC, this 265,000-square-foot, seven-story building
With four LEED Certified (silver through platinum) research buildings,
the Tempe campus of Arizona State University has provided high- has been given Silver LEED CS-Certification and is adjacent to one
of nine light-rail stops located in Tempe. The corporate office and
quality research facilities that work well for both researchers and the
environment. research lab for First Solar is located on the top floor. First Solar is the
largest manufacturer of thin film solar modules.
This effort began with the construction of the Biodesign Institute
With more than 600,000 completed square-feet of LEED Certified
at Arizona State University building (LEED Gold), which is 172,000
sq. ft., and opened in December 2004. Construction of the second research space, Tempe offers a unique environment for biotechnology
companies. The combination of high-end, environmentally sensitive
Biodesign Institute building (LEED Platinum) began shortly after and
was completed in 2006. Two more buildings are planned, for a finished research space, Arizona State University (a 65,000 student research
institution) and one of the best public transit systems in the state of
Biodesign Institute campus total of 800,000 square feet of premium
research space. Details: www.biodesign.asu.edu Arizona make Tempe an ideal location for a growing or expanding
biotechnology company.
This collaborative research and development environment allows
To get more information on Tempe, Arizona, please visit:
scientists to focus on personalized diagnostics and treatments,
outpacing infectious disease, ensuring a healthy future for our planet www.tempe.gov/business or call Technology Specialist
Dr. Alex Smith at 480 458-7448.
and ourselves as well as securing a safer world. It has lead to more
than $100 million in research funding, making the Biodesign Institute
the Valley’s single largest generator of federal biomedical research &!34&!#43
funding. Demographics:
s0OPULATION s-EDIAN!GE
Biodesign Institute researchers have formed more than 200 s-EDIAN)NCOME!GE
collaborations with clinical, industrial and research organizations. s%DUCATION!GE7ITH!T,EAST"ACHELORS$EGREE
Examples of these partnerships include collaboration with BP to Daily Community Activity:
develop cyanobacteria optimized to produce high-energy fat for s7ORKFORCE s4OURISTS-ILLION!NNUALLY
s$AILY6ISITORS s,IGHTRAILOPENS
biodiesel fuel and a working with Motorola to improve the detection of
explosives. New Projects:
s"ILLIONIN.EW0ROJECTS5NDER$EVELOPMENT
Following ASU’s $150 million investment in the Biodesign Institute s.EW#ONDOMINIUMS"EING"UILT
s-ILLION3Q&T .EW2ETAIL3PACE
campus, the City of Tempe, in partnership with Valley Metro invested in
s-ILLION3Q&T #LASS!/FlCE3PACE
a light-rail system that connects the Biodesign Institute to the additional
Corporate Who’s Who:
research institutions in Downtown Phoenix (University of Arizona s!PPLIED-ICROARRAYSs"ARDs"OSTWICK,ABORATORIESs&IRST3OLAR
Medical School and the Translational Genomics Institute). s&REESCALE3EMICONDUCTORSs)NTRINSIC"IOPROBESs-EDTRONIC
s-OTOROLA,ABSs/RTHOLOGICs3MITH"ARNEYs+0-'

BIO 2008
Gen-Probe at the Forefront of Molecular Diagnostics
By Jori Frahler Tulkki outcomes. from dangerous viruses such as HIV- such as antibody and culture testing.
Gen-Probe Inc. is proud to cel- Gen-Probe develops, manufactures 1, the hepatitis C and B viruses and Gen-Probe secured FDA approval
ebrate its 25th year of innovation as and markets molecular diagnostics the West Nile virus. for the world’s first molecular diag-
a leader in molecular diagnostics. Di- – also known as nucleic acid tests Gen-Probe’s NATs detect the nostic test in 1985 and continues to
agnostic tests are an essential part of – that provide fast, accurate, cost-ef- unique genetic sequences of micro- innovate today in fields such as on-
the health care process and provide fective results based on the human organisms that can cause infectious cology and industrial microbiology. In
critical information to physicians and genome. These products help labo- diseases or infect donated blood, as 2004, Gen-Probe received the Nation-
patients. These tests improve health ratory professionals test for a wide well as the genetic mutations that al Medal of Technology, the nation’s
status and patient outcomes, and range of microorganisms that cause can cause certain kinds of cancer. By highest honor for technological inno-
they can save health care dollars. In a range of human diseases includ- detecting disease-causing agents di- vation. This award is given to compa-
short, diagnostics promote early de- ing sexually transmitted diseases, rectly, through their unique genetic nies that “embody the spirit of Amer-
tection, which leads to more appro- tuberculosis, strep throat and pneu- fingerprints, molecular diagnostic ican innovation and have advanced
priate treatment, which in turn gen- monia. In addition, NATs safeguard tests can provide faster, more accu- the nation’s global competitiveness.”
erates better medical and economic the world’s supply of donated blood rate results than traditional methods Gen-Probe looks forward to its next
25 years of innovation in molecular
diagnostics and intends to remain at
the forefront in its field.
"O BEWFSUPSJBM TVCNJUUFE CZ (FO

1SPCF*OD+PSJ'SBIMFS5VMLLJJTUIF
BTTPDJBUFEJSFDUPSPGHPWFSONFOUBOE
DPSQPSBUF BGGBJST GPS (FO1SPCF *OD
'PS NPSF JOGPSNBUJPO QMFBTF WJTJU
XXXHFOQSPCFDPN
Science:
Continued from Page 4
be built with its own infrastructure
so all the air, electrical wiring and
plumbing may be easily modified and
turned into lab modules or clinical
space, as required.
In addition to the characteristics
described above, each life science fa-
cility must meet certain bio-safety
standards depending upon the type
of research being conducted.
(SPXJOH.BSLFU
Currently, Mercer and his life
sciences real estate team represent
Nexus Properties Inc., a leader in the
development of premier biotech fa-
cilities in the western United States
with more than one million square
feet in San Diego County. Nexus is
developing a life science campus at
La Jolla Village Drive and Interstate
805 in San Diego’s UTC community.
The two-building, 161,871-square-
foot project is under way with occu-
pancy of the first building, consisting
of 58,904 square feet, anticipated by
first quarter 2009.
According to Colliers, the lab mar-
ket in San Diego stands at approxi-
mately eight million square feet of
specialized lab space and another $4.7
million of owner-occupied lab space.
“Demand by small-tier biotech
companies – users of 3,000 to 20,000
square feet – should continue well
into 2009,” forecasts Mercer. “As
these startups continue to grow, they
will require significantly more spe-
cialized infrastructure.”
An advertorial submitted by Colliers

International Life Sciences Real Estate
Group. Sarah Wager is a practice group
coordinator at Colliers International Life
Sciences Real Estate Group. For more in-
formation, please visit www.colliers.com.
BIO 2008
Riverside County Attracts Biotech and
Medical Manufacturing Companies
By JoAnn Terrell Cornelius for industrial automation, data ac- in organic farming, agricultural re- colleges, 38 nursing and allied health
For more than half a century Riv- quisition and remote monitoring search and development, product de- education institutions, 22 hospitals,
erside County has been home to some applications, relocated to Riverside velopment, and manufacturing. Today, and a host of medical offices.
of the world’s leading pioneers in the County in 1991. we have more than 200 employees  A quality of life second to none.
biotech and medical design and man- “Moving Opto 22 from Huntington developing, manufacturing and ship- With housing prices much lower
ufacturing industries. Beach in Orange County to Temec- ping products worldwide in support of than those in surrounding counties,
Leaders in the manufacturing of ula in Riverside County was a key Nutrilite’s $2.5 billion sales.” Riverside County offers affordable,
coronary and endovascular products, corporate decision that has helped us These companies realize the many planned communities with schools,
mechanical ventilators, respiratory fuel our growth,” said Benson Houg- benefits that Riverside County, one shopping and recreational activities.
care products, imaging and diagnostic land, vice president of Opto 22. “With of the fastest-growing counties in the  An easy driving distance to most
products have all found being located access to a skilled work force, strong nation, offers, including: of the major cultural and recreational
in Riverside County advantages to new business partners, lower overall  Low-cost industrial land. offerings in Southern California and
their company and most importantly, business operating costs and a high-  A central location in the heart a location within an hour’s drive from
to their bottom line. er standard of living for Opto 22’s of inland Southern California, tra- the desert, mountains and ocean.
Biotech and medical design and employees, relocating to Riverside versed with large modern railways Companies looking to obtain a
manufacturing companies that have County has been an important factor and interstate freeways. presence in the Southern California
made their home in Riverside Coun- leading to the success we’ve enjoyed  Close proximity to Los Angeles, market, one of the largest markets
ty include Abbott Vascular, Alliance over the past 16 years.” Orange, San Bernardino and San Di- in the nation, should look no further
Environmental Group Inc., Opto 22, Nutrilite, a leading global brand of ego County markets and ports. than Riverside County.
Chemicon International Inc., Bos- vitamins, minerals and dietary sup-  A large and highly skilled labor As a business-friendly region, Riv-
ton Scientific, Rama Corporation, plements, has been located in River- force. erside County offers incentives for
VIASYS Healthcare Inc., BioTron side County since 1987.  Local support from the fully ac- qualifying businesses and boasts an
Diagnostics Inc., The Luxfer Group, “We have been producing botani- credited campus of UC Riverside, Enterprise Zone, HUB Zones, Indus-
Tellus Medical Products Inc., Pacific cal-based nutritional ingredients and which offers undergraduate and grad- trial Developments Bonds, and Fast
Consolidated Industries, Ziehm Im- functional feeds at our Lakeview fa- uate degrees in the areas of chemis- Track Permitting to qualified projects.
aging Inc., FFF Enterprises, STERIS cility since 1954,” said Neal Brophy, try; biomedical sciences; and chemical,
Isomedix Services, Medical Extru- director of global agribusiness at Nu- electrical, environmental and me- "O BEWFSUPSJBM TVCNJUUFE CZ 3JWFS
sion Technologies Inc., Nutrilite and trilite. “The location has helped in chanical engineering. It’s also the first TJEF$PVOUZ&%"+P"OO5FSSFMM$PSOF
Winslowe Environmental Inc. attracting talented people with the new medical school in the University MJVTJTTFOJPSEFWFMPQNFOUTQFDJBMJTUBU
Opto 22, a manufacturer of com- technical knowledge and skills to sup- of California system in 33 years. 3JWFSTJEF$PVOUZ&%"'PSNPSFJOGPS
puter-based hardware and software port our diverse human capital needs  Being home to seven community NBUJPO QMFBTFWJTJU XXXSJWDPFEBPSH
Cell
Culture
Lands at
Airport
Art samples
on Page 16-17
$POTUBODF8IJUFPGUIF4BO%JFHP*OUFSOBUJPOBM"JSQPSUCBMBODFTBOJNBHFPGDBODFSDFMMT
PHOTOS BY "SUXPSLBXBJUJOHJOTUBMMBUJPOJOUIF
TIM INGERSOLL 4BO %JFHP *OUFSOBUJPOBM "JSQPSUT
FROM BIOCOM 5FSNJOBM
4VTBOOB1FSFEPXJUIUIF4BO%JFHP*OUFSOBUJPOBM"JSQPSUBEKVTUTBOJNBHF
PG BO JOUFTUJOF GSPN 6$ 4BO %JFHPT /BUJPOBM $FOUFS GPS .JDSPTDPQZ BOE 5SBWFMFSTXBMLQBTUUIF$FMM$VMUVSFMJGFTDJFODFBSUFYIJCJUJO5FSNJOBMPGUIF4BO%JFHP
*NBHJOH3FTFBSDI *OUFSOBUJPOBM"JSQPSU

BIO 2008
Cell Culture: An artistic exhibit featuring microscopic
research from the San Diego life science community
San Diego International Airport | Terminal 2 | June - December 2008
B
IOCOM, the Southern California life science community and diseased organs.
San Diego International Airport present Cell Culture. Featur- The exhibit will run from June through December 2008. The exhibit
ing various pieces of art from San Diego life science research is located behind security in the upper level transition corridor of Termi-
institutions and companies, the vibrant artwork gives airport visitors nal 2 between gates 33 and 21 at the San Diego International Airport.
a visual representation of the research that more than 40,000 life sci- Images courtesy of BIOCOM, the association for the Southern California
ence employees use in creating new cures for diseases and to help save life science community, and the presenting companies and research labs.
the environment. On display will be a collection of images, sophisticated Thank you to our exhibitors: Invitrogen Corporation, J. Craig Ven-
computer models of the molecular machinery that makes life itself pos- ter Institute, Linda Nye, Pfizer La Jolla, The Salk Institute, San Diego
sible, images taken using high power laser and electron microscopes to State University, The Scripps Research Institute, Senomyx Inc., UC San
probe the microscopic processes inside cells and tissues, and stem cells Diego’s Division of Biological Sciences and National Center for Micros-
that may one day allow for the repair and regeneration of damaged and copy and Imaging Research, and Vertex San Diego.
1. 2.
3. 4. 5.
1IPUP*OEFY

$PNQVUFSHFOFSBUFEJNBHFTIPXJOHUIFJOTJEFPGBDFMM JUT
NPMFDVMBSNBDIJOFSZBOE%/"$PVSUFTZPG-JOEB4/ZF .FEJ
DBM*MMVTUSBUJPO

"NJDSPTDPQFJNBHFPGBOFXOFVSPOMBCFMFEXJUIBHSFFO
QSPUFJO JO B CSBJO SFHJPO JNQPSUBOU GPS MFBSOJOH JO NBNNBMT
$PVSUFTZPG5IF4BML*OTUJUVUFGPS#JPMPHJDBM4UVEJFT

*NBHFTPGDSZTUBMMJ[FEQSPUFJOT MFTTUIBOBNJMMJNFUFSJOTJ[F
JOWPMWFEJOUIFUSFBUNFOUPGDBODFSBOEFZFEJTFBTFT$PVSUFTZ
PG1à[FS-B+PMMB

"NBNNBMJBOLJEOFZUBHHFEXJUIáVPSFTDFOUEZFUPTIPX
6. 7. IPXTQFDJàDQBSUTXPSL$PVSUFTZPG*OWJUSPHFO$PSQPSBUJPO

+$SBJH7FOUFS*OTUJUVUF"TDBOOJOHFMFDUSPONJDSPHSBQIPG
BIO 2008
8. 9. 10.
11. 12. 13.
14. 15. 16.

CBDUFSJBUIBUDPOEVDUTFMFDUSJDJUZ CFJOHTUVEJFEUPQPUFO
'MVPSFTDFOUNBSLFSTTIPXHFOFTCFJOHFYQSFTTFEJO
$PMPSFOIBODFE JNBHFT PG NBNNBMJBO UBTUF CVET
UJBMMZIFMQNBLFDMFBOXBUFSBOEQPXFSGVFMDFMMT$PVS MJWF NBNNBMJBO DFMMT XIJDI IFMQ JEFOUJGZ BOE EFWFMPQ 5BTUFDFMMTUIBUTFOTFTXFFU CJUUFS BOETBWPSZáBWPSTBSF
UFTZPG+$SBJH7FOUFS*OTUJUVUF ESVHT GPS WBSJPVT EJTFBTFT $PVSUFTZ PG 7FSUFY 4BO %J HSFFO XIJMFUBTUFDFMMTUIBUTFOTFTPVSBSFSFE$PVSUFTZ
FHP PG4FOPNZY *OD

*NNVOPáVPSFTDFODFJNBHFPGBTUFNDFMMDPMPOZPWFS
BGFFEFSDFMMDPMPOZNBHOJàFEUJNFT$PVSUFTZPGUIF
" [FCSBàTI XJUI JUT TUFN DFMMT NJHSBUJOH BMPOH JUT
$POGPDBMáVPSFTDFOUJNBHFPGHFOFUJDBMMZFOHJOFFSFE
4BML*OTUJUVUFBOEUIF$FOUFSPG3FHFOFSBUJWF.FEJDJOFJO LJEOFZT$PVSUFTZPG6$4%T%JWJTJPOPG#JPMPHJDBM4DJ NBNNBMJBO IFBSU NVTDMF DFMM $PVSUFTZ PG 4BO %JFHP
#BSDFMPOB FODFT 4UBUF6OJWFSTJUZ

-JHIUNJDSPTDPQFJNBHFPGBNBNNBMJBOTNBMMJOUFT
"áVPSFTDFODFNJDSPTDPQFJNBHFPGB[FCSBàTIXJUI
$PNQVUFSNPEFMTIPXJOHBCBUUMFJOUIFCMPPETUSFBN
UJOF$PVSUFTZPGUIF/BUJPOBM$FOUFSGPS.JDSPTDPQZBOE JUTTUFNDFMMTWJTJCMFJOUIFUBJM$PVSUFTZPG6$4%T%JWJ CFUXFFOJNNVOFTZTUFNNPMFDVMFT CMVFBOEQJOL
BOEB
*NBHJOH3FTFBSDIBU6$4% TJPOPG#JPMPHJDBM4DJFODFT WJSBMJOWBEFS HSFFO
NBHOJàFENJMMJPOUJNFT$PVSUFTZ
PGUIF4DSJQQT3FTFBSDI*OTUJUVUF

*NNPSUBMJ[FE IVNBO DBODFS DFMMT $PVSUFTZ UIF /B
-JHIUNJDSPTDPQFJNBHFPGBNBNNBMJBOSFUJOB$PVS
UJPOBM $FOUFS GPS .JDSPTDPQZ BOE *NBHJOH 3FTFBSDI BU UFTZPGUIF/BUJPOBM$FOUFSGPS.JDSPTDPQZBOE*NBHJOH
*NNVOPáVPSFTDFODF JNBHF PG TUFN DFMMT EJWJEJOH
6$4% 3FTFBSDIBU6$4% JOBDVMUVSFNBHOJàFE UJNFT$PVSUFTZPGUIF4BML
*OTUJUVUF BOE UIF $FOUFS PG 3FHFOFSBUJWF .FEJDJOF JO
#BSDFMPOB

BIO 2008
Nova Scotia Is Where You’ll
Find Life Sciences Success
By Marli MacNeil life sciences cluster. research foundation, the province’s largest life sciences industry, but the
The word “vibrant” is often used to Statistics from a recently released proximity to major markets in the focus of the local industry is more on
describe the life sciences community asset map show that Nova Scotia has United States and Europe translates quality than quantity. The province’s
in Nova Scotia, Canada. This is a clear profitable companies with some 500 into easy access, a key factor given successful companies, R&D capabili-
indication that the sector is alive, products already in the global mar- that some 95 percent of Nova Scotia’s ties, educated work force and business
growing and has a pulse of its own. ketplace, and a healthy pipeline of life sciences products are exported. assistance programs, such as payroll
The diversity of the local industry late-stage research and development The province is also home to expe- rebates and research tax incentives,
can be seen by looking at the areas of projects. The province’s high number rienced business people who are pre- make Nova Scotia a location where
expertise that exist here: pharmaceu- of universities, combined with gov- pared to take risks. This industry is you’ll find life sciences success.
tical and therapeutics, functional food ernment research laboratories and not a get-rich-quick project. It takes
and nutraceuticals, medical technolo- research-oriented companies, result a lot of patience and dedication, and "O BEWFSUPSJBM TVCNJUUFE CZ #J
gies and diagnostics, bio information in a significant amount of scientific Nova Scotia has people who know P/PWB /PWB4DPUJBTMJGFTDJFODFTBT
technology, bioproducts, and marine knowledge that bodes well for both how to build a company that way. The TPDJBUJPO .BSMJ .BD/FJM JT UIF DIJFG
biotech. Researchers at the province’s today and the future. province’s most successful life sciences FYFDVUJWFPGmDFSPG#JP/PWB'PSNPSF
top-notch universities, hospitals and Nova Scotia offers advantages as a companies started small, did the hard JOGPSNBUJPO PO MJGF TDJFODFT JO /PWB
government labs, and suppliers who place where life sciences enterprises work, and grew slowly and steadily to 4DPUJB QMFBTF DPOUBDU .BD/FJM BU
provide specialized services to the in- will prosper. In addition to a well-ed- become leaders in their fields.
PSJOGP!CJPOPWBDB PS
dustry are also a part of the broader ucated work force and a phenomenal Nova Scotia may never boast the WJTJUXXXCJPOPWBDB
Canada: Healing, Fueling and Feeding the World

By Peter Winter tise is contributing to the advance- duction. Moreover, Canada’s strength will coordinate and fund cancer stem
The Biotechnology Industry Orga- ment of improved health across the in agricultural biotechnology is pro- cell research of both Canadian and
nization convention organizers must globe in areas such stem cells, cancer viding the world with plants that are Californian researchers, universities
have had Canada in mind when they research, genomics and vaccine de- less susceptible to disease, drought and private industries. The Ontario
developed this year’s international velopment. Canada is also position- and poor soil conditions. Institute of Cancer Research has do-
conference theme: Heal, Fuel and ing itself as a leader in bio-economy With one of the largest foreign del- nated the first $30 million to fund the
Feed the World. through the development of diverse egations to the BIO conference and consortium.
According to the spring 2008 BIO- feedstock and advanced technologies a Canadian pavilion housing nearly The CCSIP, as it relates to bio-
TECanada Insights, Canadian exper- that can be leveraged for biofuel pro- 100 companies on BIO’s exhibition technology, is also focusing on nano-
floor, Canada will demonstrate that it tech, infectious diseases, stem cells
• Industry is indeed open for business. Canada’s and solutions for sustainable energy
Specific
eNewsletters representation from all provinces such as biofuels.
• Latest Local
will provide delegates an excellent
Business opportunity to discover the high level $BOBEBT#JPUFDI*OEVTUSZ
News
Updated of biotech expertise that exists across 3FBEZGPS1BSUOFSTIJQT
Daily the country. According to the 2007 Canadian
• The Weekly Life Sciences Industry Forecast con-
Journal with $BMJGPSOJBBOE$BOBEB ducted by PricewaterhouseCoopers
archives of
past issues
8PSLJOH5PHFUIFS in collaboration with BIOTECanada,
The host city of San Diego is one Canadian biotech companies are in-
• Up to the
minute of three leading biotech clusters in creasingly expecting their funding
market the United States and thus is a key to come from strategic partners, as
quotes,
traffic and partner for the Canadian industry. opposed to venture capital sources.
weather With Canada being California’s sec- More than 30 percent identified their
These features ond largest trading partner, it is no next source of funding to come from
and more are
now available surprise that there are strong ties strategic partners compared to only
on the New between the two in biotechnology 18 percent last year. One example
San Diego
Business research, development and commer- that illustrates this trend is the re-
Journal cialization. cent deal between Eli Lilly and Com-
website.
To build on this relationship, the
Biotech
!
pany and BioMS Medical Corp. The
Canada-California Strategic Inno- two have entered into a licensing and
vation Partnership – a unique col- development agreement granting
laboration between California and Lilly exclusive worldwide rights to
Canada stakeholders from universi- BioMS Medical’s lead multiple scle-
ties, private sectors and government rosis compound, MBP8298.

– was recently established.
The CCSIP is an initiative under- 5IF$BOBEJBO
taken by senior level executives from #JPUFDIOPMPHZ*OEVTUSZ
Canadian and Californian universi- Canada’s biotechnology industry
! ties, governments and industries to is a rich source of innovation with
create institution-to-institution links almost 500 biotechnology companies
and partnerships capable of support- involved in the sector. This number
ing collaboration and exchange in ranks Canada among the leading na-
the pursuit of joint research, develop- tions with respect to the size of its
ment and delivery. biotechnology industry activities.
The Cancer Stem Cell Consortium The profile of these companies
! is just one project initiated by the shows that approximately 70 per-
Stem Cell and Regenerative Medi- cent of these firms are focusing on
cine Working Group of the CCSIP. therapeutics, diagnostics and wellness
The Cancer Stem Cell Consortium Please turn to CANADA on Page 22

BIO 2008
Canada and
San Diego
C
anada and California share
$36 billion in bilateral trade,
Succeed in
along with many complementa-
ry strengths and common con-
cerns in areas such as medical
research and drug development. As one of
the top research and technology clusters in
Biotech Together
the world, San Diego has much to gain from
closer relations with its northern neighbor.
Collaborations in research areas such as
infectious disease monitoring, cancer, stem
cells and nanotechnology are progressing.
Synergies in innovative medical devices
have also become apparent. Canada’s com-
mitment to ensuring that this partnership
continues is the focus for the Consulate of
Canada in San Diego.
Although small by most comparisons
to other diplomatic missions, the staff of
five technology and trade professionals is
active and connected. Consul Sean Barr
and his team have had considerable suc-
cess in developing a presence for Canada
within the community. Similarly, San Di-
ego’s reputation and level of awareness has
been bolstered across Canada. Since the
Consulate’s opening in 2004, hundreds of
Canadian senior executives, research pio-
neers and government officials have come
to San Diego to work with local business
and research communities. Furthermore,
the Consulate has organized missions and
exchanges from San Diego to Canada.
Dr. Cheryl Rogers, lead for the life sci-
ences sector at the Consulate, seeks to build
mutually beneficial partnerships between
San Diego and Canadian organizations and
institutes. She facilitates business-to-busi-
ness trade and investment and is available -FGUUP3JHIU4FBO#BSS $POTVMBOE)FBEPG$POTVMBUF+FOFMMF)BXLJOT 5SBEF$PNNJTTJPOFS
to provide advice, information and links to "TTJTUBOU$IFSZM3PHFST 5SBEF$PNNJTTJPOFS -JGF4DJFODFT
.JDIFMMF.PSSJT 5SBEF$PNNJT
Canada and its biotech industry. TJPOFS 64"-JGF4DJFODFT
.BSJP%JF[ 5SBEF$PNNJTTJPOFS *OGPSNBUJPO5FDIOPMPHJFT


BIO 2008
Public Biotech Companies Benefit From
Close Ties to Law Firms
By Eric J. Loumeau biotech industry comes in cycles, with In addition to the capital mar- streams. Of course, the further the
Aside from litigation and intellec- the window being closed sometimes kets, biotech companies have other biotech company is with the devel-
tual property needs, there are many for years at a time. ways to potentially generate cash. As opment of the drug in question, the
other reasons public biotech compa- Oftentimes man- many investors are becoming more better terms it can negotiate from the
nies need to develop a close working agement feels in- risk averse and now tend to wait pharmaceutical partner.
relationship with their outside legal clined to wait until until companies reach late-stage re- Whether in need of quick advice
counsel. the next milestone sults before investing. Early-stage on a corporate governance or disclo-
This decade has seen the imple- is met and the companies often look to enter into sure issue, or in need of more heavy
mentation of the Sarbanes-Oxley Act, company’s stock collaborations, licensing agreements lifting in the case of a financing or
together with related Securities and price is higher be- or sales of assets in order to gener- strategic transaction, more than ever
Exchange Commission and stock ex- fore raising money, ate cash. Pharmaceutical partners a close relationship between a public
Eric J. Loumeau
change regulations. Corporate gover- which would result can offer infrastructure, financial, biotech company and an experienced
nance issues have become even more in reduced dilution for the stockhold- and research and development re- law firm is vital.
pronounced with the recent new ex- ers. The danger with this strategy, sources to assist biotech companies
ecutive compensation disclosure re- however, is if the milestone is not in the development and distribution "O BEWFSUPSJBM TVCNJUUFE CZ
quirements and the option backdat- met. Despite the optimistic hopes of of their products, while at the same .JOU[ -FWJO $PIO 'FSSJT (MPWTLZ
ing fiasco. most biotech executives, this unfor- time reducing the biotech company’s BOE1PQFP1$&SJD+-PVNFBVJTB
In addition to the day-to-day ad- tunately happens frequently in the risk and expense. The biotech com- QBSUOFSBU.JOU[-FWJOJO4BO%JFHP
vice needed by biotech management, world of pharmaceutical research panies often receive an upfront cash 'PS NPSF JOGPSNBUJPO QMFBTF WJTJU
biotech companies need to constantly and development. The company’s payment in addition to future royalty XXXNJOU[DPN
reevaluate the necessity and timing stock price is now even lower and the
of raising money and entering into company is in an even worse posi-
strategic transactions.
Because most biotech companies
tion to raise money. Even if the mile-
stone is met, the biotech window to
BIO: UC San Diego Stem Cell Program,
will talk about the state of (stem cell)
Continued from Page 2 research, and Alan Lewis will talk
generate no revenue, they need to the capital markets may no longer be
from 4 p.m. to 5:30 p.m. Both feature about Novocell’s efforts to use stem
raise money as often as possible from open at that time. The bottom line is
presentations by local scientists. cells in pancreatic cells.”
the capital markets in order to sur- that biotech companies need to strike
“We will highlight the fact that Other critical issues this year in-
vive. Most biotech executives prefer while the iron is hot and raise the
translational research in San Diego clude how to deal with generic drugs,
to have at least two years of cash on money when the window is open, as
is really competitive and at a stage which Panetta views as having a tre-
the balance sheet at all times. Wall no one knows when the window will
worth investing in,” Panetta said. mendous impact on innovation by
Street’s appetite for investing in the close again.
Among the scientists discuss- creating an uneven playing field for
ing their views on expediting the biotechs after they’ve invested hun-
translation of research discoveries dreds of millions of dollars to create
to drugs are Joydeep Goswami, vice a drug.
president of stem cells and regen- Creating personalized medicines

erative medicine at Carlsbad-based
research kit supplier Invitrogen
and refining the development process
to create predictive technologies that

Corporation; Alan Lewis, president
and chief executive officer of San
allow researchers to target a drug’s
effectiveness on individuals could
Diego-based Novocell Inc., a stem

cell engineering company; Dr. John
save companies millions of dollars,
Panetta said.
Reed, chief executive officer of the He also expects Craig Ventor, a
La Jolla-based Burnham Institute; leading scientist of the 21st century,
Jennifer Dyer, director for the office to stir up interest in his work in bio-
of technology development at the fuels and environmental protection.
Scripps Research Institute; and Da- Sharon Bomer Lauritsen, execu-
vid Cheresh, associate director for tive vice president for food and ag-
translational research at the Moores riculture at BIO, expects the food
Cancer Center at UC San Diego. and agriculture tracks to draw much
attention given rising climate con-
5BDLMJOH(MPCBM$IBMMFOHFT cerns.
Proposition 71, the 2004 ballot “The sessions provide a great op-
initiative that authored the building portunity for the industry’s leadership
program for stem cell research and to come together to discuss solutions
led to California’s award of $271 mil- for these national and international
lion in grants to build 12 stem cell re- challenges,” Bomer Lauritsen said in
search centers in the state, remains a written statement.

a key issue. San Diego’s stem cell In the end, San Diego’s now third-

program team effort, led by UC San largest biotech cluster in the nation

Diego, the Burnham Institute, the is likely to make an even bigger mark

Salk Institute and Scripps Research on the world’s scientific map.

Institute, will receive $43 million for According to the San Diego Re-
! its building. At the BIO convention, gional Economic Development Corpo-

"
#
" $%% each institute will have a representa- ration, San Diego’s life science clus-

tive discussing its efforts on how to ter now has a yearly economic impact

move the initiative forward. of $5.3 billion in direct spending and
Said Panetta, “On June 17 we will another $3.8 billion in multiplier
have Alan Trounson, the president spending for a total impact of $9.1
of the California Institute for Re- billion a year.

generative Medicine, on the panel to
talk about what the institute is do- .BSJPO8FCCJTB3BODIP#FSOBS
ing. Larry Goldstein, director of the EPCBTFEGSFFMBODFXSJUFS
June 16, 2008 An Advertising Supplement to the San Diego Business Journal BIO 2008 Supplement 21
7JTJUVTBUCPPUI
BU#*0 BIO 2008
Canada: markers associated with the root
cause of common diseases and drug
response. Genizon’s research relies
Continued from Page 18
on DNA sampling from the Quebec
product development, according to the
Founder Population, whose extensive
Canadian Biotechnology Industry Re-
genetic sharing and low genetic vari-
port 2008. Canadian biopharmaceuti-
ability make this population ideal for
cal companies have 522 products in
gene discovery.
various stages of development, an 8
 Ibex Technologies (Montreal,
percent increase over the 2007 figure.
Quebec) sells a biomarker assay
(FOPNJDT3FTFBSDIBOE that measures the amount of real-
%FWFMPQNFOUJO$BOBEB time collagen degradation in serum,
Since 2000, Genome Canada has in- which allows researchers to monitor
vested more than $700 million across the progression of osteoarthritis and
Canada, which, when combined with rheumatoid arthritis.
funding from other partners, totals  Miraculins Inc. (Winnipeg, Man-
'PDVTPO .BOJUPCB $1.5 billion in 115 innovative research

projects and sophisticated science and
technology platforms.
The results of these projects and
itoba) is dedicated to the discovery
and validation of cancer biomarkers
for use in developing diagnostic tools
and therapeutic products.
#FQBSUPG$BOBEB±TGBTUFTUHSPXJOHCJPUFDIOPMPHZTFDUPS  Med BioGene Inc., (Vancouver,
Canada’s genomics resources have
brought the country onto the world British Columbia) is developing bio-
life sciences stage, with several sci- markers for lymphoma and leukemia
entists and the projects they direct through its Hematological Cancer
being recognized as leaders in their Profiling System, and for cardiovas-
fields. Canada is involved in numer- cular disease through its Cardiovas-
ous international projects including cular Disease Profiling System.
the Autism Genome Project, which  Phenomenome Discoveries (Sas-
links scientists undertaking autism katoon, SK) has developed a screen-
research in Canada with 170 re- ing test designed to detect markers
searchers from 10 other countries associated with cognitive impairment
worldwide. Canada is also directing and Alzheimer's disease.
the Structural Genomics Consortium,  ImmunoVaccine Technologies
an international project to deter- (Halifax, NS) is using its proprietary
mine the 3 D structures of proteins VacciMax platform to reduce the
relevant to human disease, with the number of doses of vaccine required
University of Oxford and Karolinska for protection against infectious dis-
Institutet in Stockholm, Sweden. eases like influenza.
8PSME$MBTT3FTFBSDI "HSJDVMUVSBM#JPUFDIOPMPHZ
By capitalizing on genomics, pro- It is not only in health care re-
teomics and bioinformatics, and by search that Canada excels. Canada is
allocating appropriate funding from building strong internationally com-
federal and provincial funding agen- petitive programs in plant-based ge-
cies, Canada has become a leader in nomics research. Canada has shown
the development of modern molecular the strength and capacity of its plant
diagnostic tests and in the burgeoning, science with the creation of canola,
but as yet untapped, area of molecular and the breeding of cereals and pulse
(personalized) medicine and point of crops that thrive in a harsh envi-
care testing. The country’s abundance ronment. Performance Plants Inc.,

and concentration of biomarker dis- which is headquartered in Kingston,
covery and genomics and proteomics Ontario, with research facilities in

technology platforms, as well as its Saskatoon, Saskatchewan, is a glob-
!
! internationally recognized strengths al leader in agricultural and biofuel
in clinical research, has positioned technology. The company’s patented

Canada in the forefront of personalized technologies weatherproof food crops
medicine research, and this activity is through periods of drought and heat.
spawning commercial development. These same technologies will pro-
" !!
" !! Some of the companies involved duce energy crops that will address
include: the most pressing challenges faced
""
""  GenoLogics (Victoria, British Co- by the emerging cellulosic ethanol
lumbia) offers computerized tools for industry: consistent supply of high
"
" managing, integrating and analyz- quality, competitive feedstocks that
ing scientific data for proteomics bio- meet greenhouse gas reduction man-
marker discovery and research. dates in North America and globally.

 GeneNews (Richmond Hill, On- As the BIO International Conven-
tario) is focused on the application of tion looks for solutions from global
!!!
!!! functional genomics to enable early partners in healing, feeding and fuel-
diagnosis and personalized therapeu- ing the world, Canada stands out as a
tic intervention based on disease-spe- country that can deliver on all fronts.
cific biomarkers. The company has
developed a novel approach, the Sen- "OBSUJDMFTVCNJUUFECZUIF#VSSJMM
tinel Principle, to detect and stage $BOBEJBO#JPUFDI/FXT1FUFS8JOUFS
virtually any disease or medical con- JT UIF GPVOEFS BOE FEJUPSJODIJFG PG
dition from a simple blood sample. UIFXFFLMZCJPUFDIOPMPHZQVCMJDBUJPO
 Genizon Biosciences (St. Lau- 'PS JOGPSNBUJPO PO $BOBEBT FWFOUT
rent, Quebec) is involved in the dis- BUUIF#*0*OUFSOBUJPOBM$POWFOUJPO
covery of GeneMaps, genes and bio- QMFBTFWJTJUIUUQDBOBEBCJPHDDB
T: 10 in
IF YOU HAVE BIG

IDEAS
DON’T MISS THIS BIG
OPPORTUNITY
Introducing Ontario’s
Next Generation Of Jobs Fund.
From the BlackBerry wireless revolution to groundbreaking
stem cell research, innovation and imagination are the
cornerstones of Ontario’s diverse and growing economy.
Ontario is introducing an exciting new initiative to help

ensure the continued growth of the industries that will
shape our future.
The Ontario Next Generation Of Jobs Fund is a five-year
T: 13.625 in
TO LEARN MORE ABOUT DOING $1.15 billion strategy designed to assist innovative and
environmentally proactive companies working in fields
BUSINESS IN ONTARIO, VISIT THE
as diverse as biotechnology, sustainable energy, digital
ONTARIO PAVILION NO. 4625 AT media and health sciences.
BIO 2008. SAN DIEGO, JUNE 17 – 20.
For companies prepared to advance a project over $25
million or create and/or retain 100 high value jobs within
five years for Ontarians, the Next Generation Of Jobs Fund
represents a unique opportunity to develop new products
and new markets. Companies are guaranteed a decision
within 45 days of submitting a complete proposal.
Applications for the Next Generation Of Jobs Fund are

being accepted now. For more information on the
application process and eligibility, please visit us at
nextgenjobs.ca
1- 8 0 0 - 8 19 - 8 7 0 1
Paid for by the Government of Ontario.
June 16, 2008 An Advertising Supplement to the San Diego Business Journal BIO 2008 Supplement 23
BIO 2008 lege of Medicine without using a car.
Arizona: • Drug development giant Covance
is building a 200,000-square-foot
Continued from Page 8 medical research facility in Chandler,
the iPlant Collaborative, a cyberin- a suburb of Phoenix. W.L. Gore & As-
frastructure project that will inte- sociates Inc. opened a 130,000-square-
grate previously dispersed and un- foot expansion in Flagstaff last year
connected efforts of plant scientists, and is planning a northern Phoenix
computer and information scien- campus for an additional 800 staff in
tists, mathematicians, and engineers its medical devices operations.
around the world. • North of Tucson, in Oro Valley—
• The UA College of Medicine— named by Fortune Small Business as
Phoenix, in partnership with ASU, one of the 50 “Best Places to Live and
opened its doors to last fall with Launch”—pharmaceuticals power-
plans to admit 150 students annu- house sanofi-aventis broke ground in
ally by 2012. The college is part of November on a 110,000-square-foot
the Phoenix Biomedical Campus and expansion. Another Oro Valley firm,
key campus tenants include TGEN; 5IF#SFBVMU3FTFBSDI0SHBOJ[BUJPOJTMPDBUFEJO5VDTPO "SJ[ IPNFPGi0QUJDT7BMMFZ u Ventana Medical Systems Inc., is re-
International Genomics Consortium; BIPUCFEPGPQUJDTDPNQBOJFTBOESFTFBSDI portedly also looking to grow, since
National Institute of Diabetes and its acquisition by Swiss drug devel-
Digestive and Kidney Diseases; Bar-
Flagstaff has launched its own in- 1SJWBUF4FDUPS$SFBUFT
oper Roche Holding AG.
cubator, operated by the new North- "EEJUJPOBM.PNFOUVN
row Neurological Institute; Arizona “Arizona’s bioscience community
Biomedical Collaborative building; ern Arizona Center for Emerging The private sector has also stepped
is diverse enough that any bioscience
and UA College of Pharmacy. Imme- Technologies, sited on the campus of forward, building infrastructure and
firm should feel comfortable here,”
diately adjacent to the campus is the the U.S. Geological Survey, adjacent excitement.
said Eaton. “This includes companies
ASU College of Nursing & Health- to a planned 200,000-square-foot sci- • Papago Gateway Center, a new developing new medicines, medical
care Innovation and Phoenix Union ence and technology park. state-of-the-art research facility, devices or diagnostic products, as
Bioscience High School. “Arizona is becoming widely viewed opened recently in Papago Park Cen- well as those in the agricultural, en-
Arizona is also well-positioned as having the research infrastructure ter, a $3.3 million, 350-acre, Class A vironmental and bioenergy fields.”
to support early-stage companies. and critical mass of companies neces- office and technology park. Developed
Like ASU, UA has an established sary to sustain a dynamic bioscience by San Diego-based Chesnut Proper- "OBEWFSUPSJBMTVCNJUUFECZUIF"SJ
research park that nurtures both industry,” said Robert Eaton, president ties, this 265,000-square-foot, seven- [POB %FQBSUNFOU PG $PNNFSDF +BZF
nascent and established firms. Now and chief executive officer of the Arizo- story building is silver LEED-CS 0%POOFMMJTUIFTFOJPSEJSFDUPSPGNBS
Tucson is developing a second, more na BioIndustry Association, the state- certified and located adjacent to one LFUJOH BOE CVTJOFTT BUUSBDUJPO GPS UIF
focused Arizona Bioscience Park, wide bioscience industry association of nine light-rail stops in Tempe, en- "SJ[POB%FQBSUNFOUPG$PNNFSDF'PS
designed to offer additional com- and Arizona affiliate of the national abling tenants to travel to the Biode- NPSFJOGPSNBUJPO QMFBTFDBMM

mercial lab space. Biotechnology Industry Organization. sign Institute at ASU and the UA Col- PSWJTJUXXXB[DPNNFSDFDPN

!"##$#%!!&%"##
#'#($#%! $#%!
)*+&+,-../0#"+12#' %
' &%3+.. % 45
,% "#"%!'6' ##'
%"##0#%! #"#%
!4%!&
%#%"#($#%! $#%!
$ &*-&-7 '(#8
!5 ! !#%! '( '##
" %'##9 # "
,&
"'" '&

*+'(&((,

!
"#$ %& '% ()

Creating the Perfect Climate for Biotech.
As the global biotech industry comes to San Diego to celebrate its accomplishments and discuss its future, the City
of San Diego extends its sincere appreciation to our local biotech community for your entrepreneurship and innovations
that have led to advances in the development and delivery of products that improve the health and quality of life of people
around the world.
Your efforts have created more than 500 local companies, employing over 37,000 dedicated staff that have produced
a $9 billion annual economic impact on our local economy.
The City of San Diego is committed to maintaining the business-friendly environment that has fostered your growing
biotech community to ensure that it continues to thrive.
Our thanks can only be eclipsed by the countless number of people you’ve helped along the way.
:i\Xk`e^<Zfefd`ZGifjg\i`kp
nnn%jXe[`\^f%^fm&ZgZ`-(0%)*-%-*,'

Bio2008 06-16-08

Hochgeladen von

Dokumentinformationen

Originalbeschreibung:

Copyright

Verfügbare Formate

Dieses Dokument teilen

Dokument teilen oder einbetten

Freigabeoptionen

Stufen Sie dieses Dokument als nützlich ein?

Sind diese Inhalte unangemessen?

Copyright:

Verfügbare Formate

Bio2008 06-16-08

Hochgeladen von

Copyright:

Verfügbare Formate

AN ADVERTISING SUPPLEMENT TO THE

www.colliers.com/lifesciences Our Knowledge is your Property

Armon Mills Reo Carr

+VOF  "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM #*04VQQMFNFOU

Bringing People Together For Over 25 Years

5080 Shoreham Place, #204, San Diego, CA 92122 

t Available Land & Buildings INTERSTATE

ÌÀ>Ê>ÌÌÀiÞÃÊÊ->Ê i}°ÊÊ"ÕÀÊViÌÃÊVÕ`iÊÀÌÕiÊxääÊV«>iÃ]Ê USD

+VOF  "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM #*04VQQMFNFOU

5IF TRVBSFGPPU UXPCVJMEJOH/FYVT6OJWFSTJUZ$JUZ4DJFODF$FOUFSJTDVSSFOUMZVOEFSDPOTUSVDUJPOBUUIFJOUFSTFDUJPOPG*OUFSTUBUFBOE-B+PMMB7JMMBHF%SJWF

The Challenges and Characteristics of

#*04VQQMFNFOU "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM +VOF 

    ! ! ing bio-ocean sciences, genetics and

#*04VQQMFNFOU "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM +VOF 

Life: This drops to 15 percent by 2012.

Manitoba: The Heart of Canada’s

#*04VQQMFNFOU "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM +VOF 

Supporting the Global Life Sciences Sector

#*04VQQMFNFOU "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM +VOF 

+VOF  "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM #*04VQQMFNFOU

+VOF  "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM #*04VQQMFNFOU

"O BEWFSUPSJBM TVCNJUUFE CZ (FO

An advertorial submitted by Colliers

+VOF  "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM #*04VQQMFNFOU

11. 12. 13.

14. 15. 16.

+VOF  "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM #*04VQQMFNFOU

Canada: Healing, Fueling and Feeding the World

#*04VQQMFNFOU "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM +VOF 

+VOF  "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM #*04VQQMFNFOU

  Diego-based Novocell Inc., a stem

'PDVTPO .BOJUPCB $1.5 billion in 115 innovative research

IF YOU HAVE BIG

Ontario is introducing an exciting new initiative to help

The Ontario Next Generation Of Jobs Fund is a five-year

Applications for the Next Generation Of Jobs Fund are

Paid for by the Government of Ontario.

#*04VQQMFNFOU "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM +VOF 

Das könnte Ihnen auch gefallen

+VOF "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM #*04VQQMFNFOU

5080 Shoreham Place, #204, San Diego, CA 92122

ÌÀ>Ê>ÌÌÀiÞÃÊÊ->Êi}°ÊÊ"ÕÀÊViÌÃÊVÕ`iÊÀÌÕiÊxääÊV«>iÃ]Ê USD

+VOF "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM #*04VQQMFNFOU

5IF TRVBSFGPPU UXPCVJMEJOH/FYVT6OJWFSTJUZ$JUZ4DJFODF$FOUFSJTDVSSFOUMZVOEFSDPOTUSVDUJPOBUUIFJOUFSTFDUJPOPG*OUFSTUBUFBOE-B+PMMB7JMMBHF%SJWF

#*04VQQMFNFOU "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM +VOF

! ! ing bio-ocean sciences, genetics and

#*04VQQMFNFOU "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM +VOF

#*04VQQMFNFOU "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM +VOF

#*04VQQMFNFOU "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM +VOF

+VOF "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM #*04VQQMFNFOU

+VOF "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM #*04VQQMFNFOU

"O BEWFSUPSJBM TVCNJUUFE CZ (FO

+VOF "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM #*04VQQMFNFOU

+VOF "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM #*04VQQMFNFOU

#*04VQQMFNFOU "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM +VOF

+VOF "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM #*04VQQMFNFOU

Diego-based Novocell Inc., a stem

#*04VQQMFNFOU "O"EWFSUJTJOH4VQQMFNFOUUPUIF4BO%JFHP#VTJOFTT+PVSOBM +VOF